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In the quest of deciphering biological mechanisms, the understanding of proteins 
and their functions is a vital component. However the complexity of the proteome poses 
an immense challenge for analytical chemists to explore it comprehensively. Currently 
mass spectrometry is at the forefront of proteome analysis, providing great capabilities to 
couple with modern separation techniques for wide applications.  One major objective of 
current proteomic technologies is to identify proteins of interest among high background, 
in particular from complex biological samples. A variety of techniques have been 
developed over the years to simplify protein samples, which are broadly classified as 
enrichment, high abundance protein depletion and sample fractionation. Metal ions play 
critical roles in most protein enzymes and their interactions with proteins have been well 
documented, but their applications in proteomics are underdeveloped. We have been 
developing and applying metal-protein interaction based approaches for proteomics 
studies due to their affordability, versatility and tunability. Previously, the Tao lab 
introduced Polymer-based Metal Affinity Capture with Ti(IV) (PolyMAC-Ti) for 
phosphopeptide enrichment in solution phase as opposed to commonly used solid phase 
extraction methods. In chapter 2 we discuss further extension of PolyMAC technology to 
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PolyMAC-Zr and the use of complementary metal ion enrichment to study Syk 
dependent phosphorylation in B-cells.  In chapter 3, we discuss a study to couple 
PolyMAC-Ti with anti-phosphotyrosine antibody to investigate Syk and Lyn dependent 
phosphorylation in B-cells. In chapter 4, we introduce a method to capture and fractionate 
proteins based on copper-protein interactions. Its unique application in enriching and 









CHAPTER 1: INTRODUCTION 
 
The detection of any proteome in its entirety with current instrumentation is 
hindered by the proteome complexity for several reasons: (i) constant flux in expression 
pattern in response to internal and external stimuli (ii) diversity and heterogeneity 
between different cell types of the same organism owing to alternate splicing of mRNA 
and post translational control1 and (iii) the large dynamic range of protein abundances2.  
For example, protein abundances in human cell and plasma proteomes span over 7 and 10 
orders of magnitude respectively3 while the most sensitive mass spectrometric methods at 
present can monitor only a dynamic range of 4-5 orders of magnitude4. The large 
dynamic range of protein concentrations in biological samples poses a challenge for mass 
spectrometrists to identify low abundance proteins such as biomarkers and therapeutic 
targets in complex biological samples.  Current solutions include the enrichment of 
proteins of interest, depletion of high abundance proteins and sample fractionation5, 6. 
Targeting specific classes of proteins of interest is usually achieved based on the 
affinity between proteins and various other biological and chemical moieties5, 6. 
Antibodies are used in all three of the aforementioned methods in proteomics. Antibody-
based approaches are widely used to enrich proteins and peptides based on specific 
consensus sequences7, 8, tyrosine phosphorylation9, 10, glycosylation11, acetylation12 and 
ubiquitination13. Further, antibodies are used to deplete high abundant proteins to 
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improve the proteome coverage particularly in serum samples 14, 15. Human serum is the 
source of choice for biomarker and drug target discovery due to presence of secreted 
proteins from tissues and organs in response to varying health conditions in our body as 
well as the ease of collection. However, 22 proteins constitute 99% of the total plasma 
protein mass, and serum albumin alone accounts for 50% of it3, 16, 17. Antibody-based 
high abundance protein depletion kits are commercially available that are capable of 
depleting up to 58 most abundant proteins18-20 depending on the extent of depletion 
needed. Furthermore, immunoaffinity chromatography combines the use of liquid 
chromatography with the specific binding of antibodies or related agents21. It is a 
versatile, powerful purification method based on well-characterized antibody-target 
interactions, making it amenable for use in many applications, including 
immunoextraction22, immunodepletion23, chromatographic immunoassays24, and post-
column immunodetection25 for clinical and diagnostic assays for drugs, toxins, and 
biomarkers.  
Although antibody based methods provide high specificity and tight binding 
toward the analytes, producing high quality antibodies are time consuming and costly. 
When complex biological samples are applied, non-specific interactions and antibody 
inactivation by proteases are common problems.  Further, some antibodies may leach 
during the experimental procedures due to necessary harsh washing and elution 
conditions. Therefore non-antibody methods have been developed to provide cost 
effective and robust alternatives for sample simplification, enrichment, depletion and 
fractionation. For example, metal – phosphate affinity and hydrazide chemistry are 
commonly used as enrichment strategies prior to mass spectrometric analysis16, 17, 26in 
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phosphoproteomics and glycoproteomics respectively. Moreover, ProteoMiner27, 28 is a 
unique technology that uses a combinatorial hexapeptide library coupled beads in equal 
quantities to achieve high abundant protein depletion and low abundant protein 
enrichment in a single step. An equal number of molecules from each protein are retained 
by the beads, leading to the depletion of high abundant proteins and enriching low 
abundant proteins. However, this method can only be used to obtain qualitative 
information because the enrichment technique disrupts the protein concentration profile. 
Finally, two dimensional (2D) gel electrophoresis and a wide variety of chromatographic 
techniques have been used to fractionate protein and peptide samples prior to mass 
spectrometric analysis. Different types of chromatographic methods are available such as 
reversed phase, ion exchange, size exclusion, or affinity to be selected for protein 
separation5, 6, 29 
In the quest of developing low cost, versatile proteomics approaches, metal-
protein interaction based methods have gain immense effectiveness. The variety of 
differential interactions possible between different metals and ligands on proteins provide 
many avenues to explore this aspect. The metal-ligand interactions are classified based on 
hard soft acid base theory (HSAB)30, 31 in which all the metal ions have acid properties 
and ligands have base properties. Ca2+, Mg2+, Mn2+, Fe3+, Ti4+, Zr4+, Cr3+ and Co3+ ions 
are categorized as hard acids and interact preferentially with hard bases such as H2O, 
RCOOO- , PO4
3-, OH-, serine and threonine. Fe2+, Co2+, Ni2+, Cu2+ and Zn2+ ions are 
categorized as intermediate acids and interact preferentially with intermediate bases such 
as NO2
-, N3
-, pyridine and imidazole. Cu+, Ag+, Hg+, Pd+ and Pt+ ions are categorized as 
soft acids and interact preferentially with soft bases such as RSH, RS-, methionine and 
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cysteine30, 31. Moreover, various types of interactions have been identified between 
proteins and metal ions such as, (i) indirect interaction via organic ligands, (ii) indirect 
interaction with hydrophobic regions via inorganic ligand, (iii) supramolecular clatherate 
compounds and (iv) coordination interactions with the functional groups of amino acid 
residues30, 31. The interaction via organic ligands occurs through bridged complexes, for 
example, iron-porphyrin units in hemoglobin and the metal-phosphate interaction. At 
present, the metal-phosphate chemistry is the major enrichment strategy used in 
phosphoproteomics.  Heavy metal ions such as mercury and gold interact with 
hydrophobic regions of protein molecules through inorganic ligands such as iodide. The 
iron storage protein ferretin forms a supramolecular clatherate in which Fe3+ is 
incorporated in the cavity formed by multiple ferretin units. The formation of 
coordination bonds between the metals and amino acids play a significant role in the 
structure and function of metal-protein systems. The possible coordination sites on 
proteins are carboxylic groups, peptide bonds, amine groups, hydroxyl groups (serine, 
threonine, and tyrosine), thiol groups (cysteine), and imidazole (histidine). The different 
combinations of coordination sites, coordination structures, bond nature, and metal ions 
create a wide variety of possibilities for metal-protein interactions30, 31. Therefore we 
focused on further exploring the metal-protein interactions for proteomics applications 
and in this thesis we present applications of Polymer-based Metal Affinity Capture 
(PolyMAC) for phosphopeptide enrichment and Immobilized Metal Affinity 





1.1 Phosphopeptide Enrichment 
Many different approaches have been employed for phosphopeptide enrichment 
to date and can be mainly categorized under affinity purification, chemical derivatization 
and chromatographic separation techniques. As an example, phosphorylated peptides and 
proteins can be affinity-purified by antibodies capable of recognizing specific regions or 
phosphorylated residues. Such methods, however, have demonstrated useful applications 
mostly in enrichment of tyrosine phosphorylated proteins and peptides32, 33.   For more 
global analyses, affinity-based methods using Immobilized Metal ion Affinity Capture 
(IMAC) and Metal Oxide Affinity Capture (MOAC) exploit the formation of coordinate 
bonds between the negatively charged phosphate group and the metal ions. Fe (III) 34, 35 , 
Ga (III) 36, Al(III) and Ca(II)37 have shown good affinity toward phosphate groups, and 
Fe(III) has especially been extensively used in IMAC. More recently, a much more 
specific set of Ti(IV)- and Zr(IV)-functionalized IMAC beads have also been introduced.  
MOAC is based on the same basic principles as IMAC, where titanium dioxide 38, 39 and 
zirconium dioxide 40, 41 have been successfully used for phosphopeptide capturing and 
applied in numerous biological studies42, 43.  
Another phosphopeptide capture approach is based on selective modification of a 
phosphate group preceding enrichment and is known as chemical derivatization. This has 
been achieved through beta-elimination of a phosphate group, followed by Michael 
addition of a stable chemical group such as 1,2-ethanedithiol. These modified peptides 
may subsequently be affinity-purified using a relatively simple capture step, such as 
biotin-avidin interaction44, 45. Further, derivertization of phosphate to has been used to 
covalently couple phosphopeptides on to a poly(amine) dendrimer in a single step46. This 
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method has been successfully applied to identify and quantify phosphopeptides from 
complex mixtures. In theory, this method improves the fragmentation efficiency during 
MS/MS by avoiding neutral loss and increases the ionization efficiency by decreasing the 
negative charge of phosphopeptides. However, the extensive sample loss and unavoidable 
side reactions have limited the usefulness of chemical derivatization47.  
Furthermore, chromatographic techniques such as strong cation exchange 
(SCX)48, strong anion exchange (SAX)49 and hydrophilic interaction chromatography 
(HILIC)50 have been applied directly for phosphopeptide enrichment. SCX and SAX 
separate molecules based on the charge. The SCX stationary phase has negatively 
charged functional groups that retain cations under acidic conditions so it is possible to 
elute phosphopeptides in earlier fractions51-53, whereas SAX has reversed polarity and 
separation properties. HILIC utilizes a hydrophilic stationary phase allowing the analyte 
to interact through hydrogen bonding, which retains phosphorylated peptides longer on 
the column50. Although the initial attempts were made to use SCX, SAX and HILIC 
directly for phosphopeptide enrichment, the experimental data suggest that by themselves 
they are not very practical due to low specificity. At present, such separation techniques 
are essentially used to pre-fractionate peptides in large scale phosphoproteomics studies 
in combination with more specific enrichment methods, such as IMAC and MOAC, to 
simplify the sample complexity42, 43.  
The current most popular enrichment approaches, IMAC and MOAC, chelate 
phosphopeptides to an affinity group mounted on a solid support, resulting in 
heterogeneous reaction conditions that can lead to poor binding site accessibility and low 
reproducibility. As a solution, the Tao lab recently introduced Polymer-based Metal ion 
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Affinity Capture (PolyMAC), a reagent based on a titanium (IV)-functionalized poly 
amidoamine (PAMAM) dendrimer, which showed exceptionally high reproducibility and 
selectivity 9. A dendrimer is a soluble, polymeric nano material with a globular protetin-
like structure which provides easily modifiable surface functional groups. In chapter 2 we 
discuss the development of PolyMAC-Zr, a novel zirconium (IV)-functionalized 
PAMAM G4 dendrimer, capable of effective enrichment of a unique array of 
phosphopeptides and the use of complementary phosphopeptide enrichment of 
PolyMAC-Ti and PolyMAC-Zr to investigate Syk dependent phosphorylation in B cells. 
In chapter 3 we present enrichment of tyrosine phosphorylated peptides using 
phosphotyrosine antibody and PolyMAC-Ti in sequential to investigate Syk- and Lyn-
dependent events in B cells.  
 
1.2 Isolation of Low Concentration Proteins from Complex Matrices 
Not only the proteome complexity, but also the complexity of the sample matrix 
adds upon the difficulty of identification of low abundance proteins. Therefore, many 
sample purification methods have been developed over the years to eliminate matrix 
molecules such as lipids, metabolites and detergents. The earliest approaches utilized the 
relative solubility of proteins in which the protein component was precipitated by 
changing the properties of the solvent54. Some examples are, addition of salts, organic 
solvents such as acetone, varying the pH or the temperature54, 55. However, incomplete 
protein precipitation is a common problem in solubility based methods. More recently 
Filter-Aided Sample Preparation (FASP)56 was introduced to purify protein samples from 
complex matrices. In FASP, proteins are retained on a membrane while the low 
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molecular weight components and detergents pass through the membrane. Thus retained 
proteins are digested and eluted for further analysis. However, FASP suffers from lengthy 
sample preparation times, sample loss and incomplete removal of detergents. 
Protein sample purification and simplification can be achieved simultaneously 
using 2D gel electrophoresis or chromatographic techniques. Since it was first 
introduced57, 2D gel electrophoresis has evolved at different levels and become a 
powerful technique for protein separation and the method of choice for differential 
protein expression analysis. This technique has an excellent resolving power; it is 
possible to visualize over 10,000 spots corresponding to over 1,000 proteins on a single 
gel as well as multiple spots containing different molecular forms of the same protein58. 
Nevertheless, it suffers from several major limitations related to reproducibility59, poor 
representation of low abundant proteins60, proteins at the extremes of acidity, basicity, 
size and hydrophobicity61, and difficulties in automation of gel-based techniques62. 
Moreover, the co-immigration of multiple proteins in a single spot makes quantification 
difficult. 
Due to aforementioned limitations in gel electrophoresis, most recent 
developmental efforts have been focused on chromatographic techniques. Proteins can be 
separated based on physical properties including shape, charge and size, as well as 
chemical properties such as isoelectric point (pI), hydrophobicity and affinity to various 
ligands5. In chromatography protein fractionation is achieved by manipulating either the 
mobile phase or the stationary phase5, 6, 29. Mobile phase properties can be altered by 
changing the slope (time) of the gradient, buffer pH and salt concentration, as well as 
using various additives5, 6, 29. Different types of stationary phases are available such as 
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reversed phase (C4, C8 etc.), ion exchange (SCX), size exclusion, normal phase (silica), 
or affinity (antibody, apatmer, biotin etc.) to be selected for protein separation5, 6, 29.  
The basic principle of affinity chromatography is based on the ability of proteins 
to bind selectively and reversibly to a complementary molecule attached to a solid 
support5, 63. Thus, proteins that do not poses complementary binding sites for the affinity 
ligands pass directly through the column or can be eluted easily in early fractions. The 
bound proteins are then eluted in the reverse order of the strength of the interaction. 
Although antibodies directed against specific proteins or a group of proteins remain the 
most popular affinity method, there are numerous other methods that have been 
developed over the years. These methods include lectin affinity for glycoproteins64-67, 
immobilized metal affinity chromatography (IMAC) containing nickel for histidine 
tagged protein68 and gallium for phosphoproteins36. While studying metal-protein 
interaction with different metals immobilized on IMAC, we observed that Cu2+ 
demonstrated a unique ability to capture over 98% of the protein component of cell lysate 
and serum samples. Furthermore, it was capable of successfully isolating secreted 
proteins over FASP from the complex matrix. This suggested that copper – protein 
interaction can be applied to capture proteins from complex mixtures and matrices and 
subsequently fractionate to identify low abundant proteins. In chapter 4, we describe the 
development of IMAC-Cu based protein fractionation method and its application to 







(1) Peng, J.; Gygi, S. P. J Mass Spectrom 2001, 36, 1083-1091. 
 
(2) Corthals, G. L.; Wasinger, V. C.; Hochstrasser, D. F.; Sanchez, J. C. 
Electrophoresis 2000, 21, 1104-1115. 
 
(3) Anderson, N. L.; Anderson, N. G. Mol Cell Proteomics 2002, 1, 845-867. 
 
(4) Picotti, P.; Bodenmiller, B.; Mueller, L. N.; Domon, B.; Aebersold, R. Cell 2009, 
138, 795-806. 
 
(5) Issaq, H. J.; Conrads, T. P.; Janini, G. M.; Veenstra, T. D. Electrophoresis 2002, 
23, 3048-3061. 
 
(6) Ly, L.; Wasinger, V. C. Proteomics 2011, 11, 513-534. 
 
(7) Gronborg, M.; Kristiansen, T. Z.; Stensballe, A.; Andersen, J. S.; Ohara, O.; 
Mann, M.; Jensen, O. N.; Pandey, A. Mol Cell Proteomics 2002, 1, 517-527. 
 
(8) Pandey, A.; Fernandez, M. M.; Steen, H.; Blagoev, B.; Nielsen, M. M.; Roche, S.; 
Mann, M.; Lodish, H. F. J Biol Chem 2000, 275, 38633-38639. 
 
(9) Iliuk, A. B.; Martin, V. A.; Alicie, B. M.; Geahlen, R. L.; Tao, W. A. Mol Cell 
Proteomics 2010, 9, 2162-2172. 
 
(10) Villen, J.; Beausoleil, S. A.; Gerber, S. A.; Gygi, S. P. Proc Natl Acad Sci U S A 
2007, 104, 1488-1493. 
 
(11) Pan, S.; Chen, R.; Aebersold, R.; Brentnall, T. A. Mol Cell Proteomics 2011, 10, 
R110 003251. 
 
(12) Guan, K. L.; Yu, W.; Lin, Y.; Xiong, Y.; Zhao, S. Nat Protoc 2010, 5, 1583-1595. 
 
(13) Jayasundera, K. B.; Iliuk, A. B.; Nguyen, A.; Higgins, R.; Geahlen, R. L.; Tao, 
W. A. Anal Chem 2014, 86, 6363-6371. 
 
(14) Liu, T.; Qian, W. J.; Gritsenko, M. A.; Camp, D. G., 2nd; Monroe, M. E.; Moore, 
R. J.; Smith, R. D. J Proteome Res 2005, 4, 2070-2080. 
 
(15) Plavina, T.; Wakshull, E.; Hancock, W. S.; Hincapie, M. J Proteome Res 2007, 6, 
662-671. 
 
(16) Ray, S.; Reddy, P. J.; Jain, R.; Gollapalli, K.; Moiyadi, A.; Srivastava, S. 





(17) Surinova, S.; Schiess, R.; Huttenhain, R.; Cerciello, F.; Wollscheid, B.; 
Aebersold, R. J Proteome Res 2010, 10, 5-16. 
 
(18) Gao, M.; Deng, C.; Yu, W.; Zhang, Y.; Yang, P.; Zhang, X. Proteomics 2008, 8, 
939-947. 
 
(19) Levin, Y.; Schwarz, E.; Wang, L.; Leweke, F. M.; Bahn, S. J Sep Sci 2007, 30, 
2198-2203. 
 
(20) Zolotarjova, N.; Mrozinski, P.; Chen, H.; Martosella, J. J Chromatogr A 2008, 
1189, 332-338. 
 
(21) Hage, D. S.; Kao, P. C. Anal Chem 1991, 63, 586-595. 
 
(22) Strathmann, F. G.; Laha, T. J.; Hoofnagle, A. N. Clin Chem 2011, 57, 1279-1285. 
 
(23) Patel, B. B.; Barrero, C. A.; Braverman, A.; Kim, P. D.; Jones, K. A.; Chen, D. 
E.; Bowler, R. P.; Merali, S.; Kelsen, S. G.; Yeung, A. T. J Proteome Res 2012, 
11, 5947-5958. 
 
(24) Ghosh, R. Biotechnol Bioeng 2006, 93, 280-285. 
 
(25) Tang, Z.; Karnes, H. T. Biomed Chromatogr 2000, 14, 442-449. 
 
(26) Pernemalm, M.; Lewensohn, R.; Lehtio, J. Proteomics 2009, 9, 1420-1427. 
 
(27) Sennels, L.; Salek, M.; Lomas, L.; Boschetti, E.; Righetti, P. G.; Rappsilber, J. J 
Proteome Res 2007, 6, 4055-4062. 
 
(28) Thulasiraman, V.; Lin, S.; Gheorghiu, L.; Lathrop, J.; Lomas, L.; Hammond, D.; 
Boschetti, E. Electrophoresis 2005, 26, 3561-3571. 
 
(29) Abdallah, C.; Dumas-Gaudot, E.; Renaut, J.; Sergeant, K. Int J Plant Genomics 
2012, 2012, 494572. 
 
(30) Haas, K. L.; Franz, K. J. Chem Rev 2009, 109, 4921-4960. 
 
(31) Bezrukov, M. G.; Belousova, A. M.; Sergeev, V. A. Russian Chemical Reviews 
1987, 51, 397-406. 
 
(32) Olsen, J. V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.; Mortensen, P.; Mann, 
M. Cell 2006, 127, 635-648. 
 






(34) Porath, J. J Chromatogr 1988, 443, 3-11. 
 
(35) Neville, D. C.; Rozanas, C. R.; Price, E. M.; Gruis, D. B.; Verkman, A. S.; 
Townsend, R. R. Protein Sci 1997, 6, 2436-2445. 
 
(36) Posewitz, M. C.; Tempst, P. Anal Chem 1999, 71, 2883-2892. 
 
(37) Gaberc-Porekar, V.; Menart, V. J Biochem Biophys Methods 2001, 49, 335-360. 
 
(38) Pinkse, M. W.; Uitto, P. M.; Hilhorst, M. J.; Ooms, B.; Heck, A. J. Anal Chem 
2004, 76, 3935-3943. 
 
(39) Larsen, M. R.; Hojrup, P.; Roepstorff, P. Mol Cell Proteomics 2005, 4, 107-119. 
 
(40) Zhou, H.; Xu, S.; Ye, M.; Feng, S.; Pan, C.; Jiang, X.; Li, X.; Han, G.; Fu, Y.; 
Zou, H. J Proteome Res 2006, 5, 2431-2437. 
 
(41) Kweon, H. K.; Hakansson, K. Anal Chem 2006, 78, 1743-1749. 
 
(42) Guo, H.; Isserlin, R.; Chen, X.; Wang, W.; Phanse, S.; Zandstra, P. W.; Paddison, 
P. J.; Emili, A. Proteomics 2013, 13, 1325-1333. 
 
(43) Yu, P.; Pisitkun, T.; Wang, G.; Wang, R.; Katagiri, Y.; Gucek, M.; Knepper, M. 
A.; Geller, H. M. PLoS One 2013, 8, e59285. 
 
(44) Adamczyk, M.; Gebler, J. C.; Wu, J. Rapid Commun Mass Spectrom 2001, 15, 
1481-1488. 
 
(45) Weckwerth, W.; Willmitzer, L.; Fiehn, O. Rapid Commun Mass Spectrom 2000, 
14, 1677-1681. 
 
(46) Tao, W. A.; Wollscheid, B.; O'Brien, R.; Eng, J. K.; Li, X. J.; Bodenmiller, B.; 
Watts, J. D.; Hood, L.; Aebersold, R. Nat Methods 2005, 2, 591-598. 
 
(47) Beltran, L.; Cutillas, P. R. Amino Acids 2012, 43, 1009-1024. 
 
(48) Beausoleil, S. A.; Jedrychowski, M.; Schwartz, D.; Elias, J. E.; Villen, J.; Li, J.; 
Cohn, M. A.; Cantley, L. C.; Gygi, S. P. Proc Natl Acad Sci U S A 2004, 101, 
12130-12135. 
 
(49) Han, G.; Ye, M.; Zhou, H.; Jiang, X.; Feng, S.; Tian, R.; Wan, D.; Zou, H.; Gu, J. 
Proteomics 2008, 8, 1346-1361. 
 





(51) Dai, J.; Jin, W. H.; Sheng, Q. H.; Shieh, C. H.; Wu, J. R.; Zeng, R. J Proteome 
Res 2007, 6, 250-262. 
 
(52) Lim, K. B., Kassel, D.B. Anal. Biochem 2006, 354, 213-219. 
 
(53) Nie, S.; Dai, J.; Ning, Z. B.; Cao, X. J.; Sheng, Q. H.; Zeng, R. J Proteome Res, 9, 
4585-4594. 
 
(54) Burgess, R. R. Methods Enzymol 2009, 463, 331-342. 
 
(55) Jiang, L.; He, L.; Fountoulakis, M. J Chromatogr A 2004, 1023, 317-320. 
 
(56) Wisniewski, J. R.; Zougman, A.; Nagaraj, N.; Mann, M. Nat Methods 2009, 6, 
359-362. 
 
(57) O'Farrell, P. H. J Biol Chem 1975, 250, 4007-4021. 
 
(58) Schulze, W. X.; Usadel, B. Annu Rev Plant Biol 2010, 61, 491-516. 
 
(59) Lilley, K. S.; Razzaq, A.; Dupree, P. Curr Opin Chem Biol 2002, 6, 46-50. 
 
(60) Gygi, S. P.; Corthals, G. L.; Zhang, Y.; Rochon, Y.; Aebersold, R. Proc Natl 
Acad Sci U S A 2000, 97, 9390-9395. 
 
(61) Ong, S. E.; Pandey, A. Biomol Eng 2001, 18, 195-205. 
 
(62) Tonge, R.; Shaw, J.; Middleton, B.; Rowlinson, R.; Rayner, S.; Young, J.; 
Pognan, F.; Hawkins, E.; Currie, I.; Davison, M. Proteomics 2001, 1, 377-396. 
 
(63) Lee, W. C.; Lee, K. H. Anal Biochem 2004, 324, 1-10. 
 
(64) Lefebvre, T.; Cieniewski, C.; Lemoine, J.; Guerardel, Y.; Leroy, Y.; Zanetta, J. 
P.; Michalski, J. C. Biochem J 2001, 360, 179-188. 
 
(65) Machuka, J.; Okeola, O. G. J Agric Food Chem 2000, 48, 2296-2299. 
 
(66) Mansour, M. H. J Parasitol 1996, 82, 586-593. 
 
(67) Young, N. M.; Brisson, J. R.; Kelly, J.; Watson, D. C.; Tessier, L.; Lanthier, P. 
H.; Jarrell, H. C.; Cadotte, N.; St Michael, F.; Aberg, E.; Szymanski, C. M. J Biol 
Chem 2002, 277, 42530-42539. 
 
(68) Ji, J.; Chakraborty, A.; Geng, M.; Zhang, X.; Amini, A.; Bina, M.; Regnier, F. J 










CHAPTER 2: POLYMAC-Zr FOR PHOSPHOPEPTIDE ENRICHMENT 
 
2.1 Introduction 
B cells are a vital component of the adaptive immune system that recognize 
foreign antigens  through a cell surface immunoglobulin known as the B cell receptor 
(BCR) for antigen1. B cell activation through BCR stimulation results in proliferation and 
differentiation of B cells to form both antibody-producing and memory cells. Cross-
linking the BCR by antigen engagement initiates phosphorylation of immunoreceptor 
tyrosine-based activation motifs (ITAMs) by the Src-family kinase, Lyn and subsequent 
recruitment of the tyrosine kinase, Syk.  Multiple adaptor proteins and effector proteins 
including the B-cell linker protein BLNK, the guanine nucleotide exchange factor Vav, 
phospholipase C- (PLC),  and phosphatidylinositide 3-kinase (PI3K)  associate  to 
form signaling complexes2 that trigger downstream pathways such as  activation of Btk, 
mobilization of  Ca2+ 3 and activation of the Ras/MEK/ERK pathway. The interaction 
between a phosphorylated ITAM and the SH2 domains of Syk, coupled with the 
phosphorylation of the kinase on tyrosine, is essentially required for all BCR-mediated 
signaling events.    
The contribution of Syk to the adaptive immune response in B cells is well known 
and characterized. However, studies have also identified a large number of diverse 





maturation, platelet activation and vascular development2.  The involvement of Syk in the 
pathogenesis of allergy, autoimmune diseases, carcinoma and hematological 
malignancies has made it an important therapeutic target2, 4-6. Thus, knowledge of the 
downstream pathways that mediate the diverse functions of Syk are of considerable 
interest. As Syk is a tyrosine kinase, most studies have focused on Syk-dependent 
tyrosine phosphorylation,7 which is largely limited to  immediate downstream signaling 
events and direct substrates8. Since Syk functions upstream of multiple pathways of 
which serine/threonine kinases (e.g., PKC, Erk, Akt, etc.) are major components, changes 
in its activity would be expected to affect many downstream events regulated by protein 
phosphorylations on serines and threonines. This study was designed to identify Syk-
dependent downstream pathways in activated B cells at the proteomics level, focusing 
mainly on such serine and threonine phosphorylation events.  
Mass spectrometry is the major tool for analyzing protein phosphorylation in a 
high throughput manner. Phosphopeptide enrichment is a necessary prerequisite in 
phosphoproteomics due to the low stoichiometry of protein phosphorylation and the low 
abundance of phosphoproteins9, 10. Many different approaches have been employed for 
phosphopeptide enrichment11, and can be categorized mainly under affinity purification10, 
12-20, chemical derivatization21, 22 and chromatographic separation23-25. The most popular 
enrichment approaches, immobilized metal ion affinity chromatography (IMAC)13-16 and 
metal oxide affinity chromatography (MOAC)17-20, chelate phosphopeptides to an affinity 
group mounted on a solid support. This heterogeneous condition can lead to poor binding 
accessibility and low reproducibility. Recently we introduced Polymer-based Metal ion 





PAMAM dendrimer, which demonstrated  enhanced reproducibility and selectivity26. 
Other studies have shown  the effectiveness of using both Zr- and Ti-based reagents for 
phosphopeptide enrichment, as well as the ability of each to capture a unique set of 
phosphopeptides27. Therefore, to complement our titanium-bound nanopolymer, we 
developed PolyMAC-Zr, a zirconium (IV)-functionalized PAMAM G4 dendrimer. Here, 
we present PolyMAC-Zr as a novel reagent for phosphopeptide enrichment and utilize 
the complementary PolyMAC-Ti and PolyMAC-Zr enrichment methods to examine the 
role of Syk-dependent phosphorylation in BCR signaling. Quantitative 
phosphoproteomics based on Stable Isotope Labeling via Amino Acid in Culture 
(SILAC)28 was employed to identify downstream effectors of Syk. Using the Syk 
substrate-site inhibitor piceatannol7 and comprehensive sample fractionation with reverse 
phase liquid chromatography (RPLC) or hydrophilic interaction chromatography 
(HILIC), we were able to quantify close to 5,000 sites of phosphorylation that were 
significantly affected by the activity of Syk  after BCR stimulation from over 16,000 
identified unique phosphorylation sites. Functional and pathway annotations confirmed 
many known functions of Syk, but also revealed potential novel roles including a role in 











2. 2 Methods 
 
 
2.2.1 Synthesis of PolyMAC-Zr Reagent 
 
Polyamidoamine dendrimer generation 4 (PAMAM G4) solution (200 µl; 
provided as 10% wt/vol in methanol; Sigma-Aldrich) was dried in a microcentrifuge tube 
and redissolved in 1 ml of dimethyl sulfoxide. Then 6 mg of Boc-aminooxy acetic acid, 
15 mg of N-Hydroxybenzotriazole (HOBt) and 10 µl of N,N'-Diisopropylcarbodiimide 
(DIC) were dissolved in 1 ml of DMSO in a microcentrifuge tube and reacted for 30 min 
at room temperature with shaking. The above two solutions were transferred into a 10 ml 
round-bottom flask and stirred overnight at room temperature. Then 3 ml of water was 
added to the reaction mixture and dialyzed against water to remove excess reagents and 
concentrated using a 3500 molecular weight cut-off centrifugal filter. The mixture was 
transferred to a 10 ml round-bottom flask and an equal volume of 250 mM MES (2-(N-
morpholino) ethyanesulfonic acid; pH 5.5) buffer was added to it.  Next 16 mg of 
carboxyethyl phosphonic acid, 16 mg of N-hydroxysuccinimide and 160 mg EDC (1-
ethyl-3-(3-dimethylaminopropyl)carbidiimide hydrochloride) were added to the mixture 
and stirred overnight at room temperature. The solution was dialyzed against water and 
one-third of it was reacted with 0.1 M solution of ZrOCl2 for 1 1/2 hours at room 
temperature. The mixture was dialyzed against water and transferred to a glass tube and 
evaporated to complete dryness. Then the solid was redissolved in 80% trifluoroacetic 
acid, reacted for 1 1/2 hours and evaporated under N2 gas. The mixture was dialyzed 
successively in 1:4 DMSO: water mixture and water. The final PolyMAC-Zr product was 





2.2.2 Isolation of Phosphopeptides from DG75 Cell Lysates 
DG-75 cell culture was grown to 80% confluency in RPMI-1640 media (Gibco) 
substituted with 10% inactivated FBS, 1% sodium pyruvate, 0.5% treptomycin/penicillin, 
and 0.05% β-mercaptoethanol. Then the cells were washed with PBS, collected, and 
frozen at -80 °C. Cells were lysed in 1 mL of lysis solution (50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1x phosphatase inhibitor 
cocktail (Sigma-Aldrich), 10 mM sodium fluoride) for 20 minutes on ice. The resulting 
mixture was centrifuged at 16,100 × g for 10 minutes, and supernatant containing soluble 
proteins was collected. The protein concentration was measured using the BCA assay. 
DG-75 protein lysate was denatured and reduced in 50 mM trimethyl ammounium 
bicarbonate containing 0.1% RapiGest and 5 mM dithiothreitol for 30 minutes at 50 °C. 
The proteins were further alkylated in 15 mM iodoacetamide for 1 hour in the dark at 
room temperature, and digested with proteomics grade trypsin at 1:100 ratio overnight at 
37 °C. The pH was adjusted below 3 with hydrochloric acid and the sample was 
incubated for 40 minutes at 37 °C. The sample was centrifuged at 16,100 × g and 
supernatant collected. The resulting peptides were desalted with a Sep-Pak C18 column. 
The enrichment of phosphopeptides was carried out using 100 µg samples, according to 
the protocol described below.  
 
2.2.3 Phosphopeptide Enrichment 
The peptide mixture was dissolved in 100 µl of the loading buffer (200 mM 
glycolic acid, 1% trifluoroacetic acid and 50% acetonitrile), 5 nmol of PolyMAC-Zr was 





buffer (300 mM HEPES buffer at pH 7.7) was added to increase the pH above 6.3 and 
transferred to a spin column (Boca Scientific) containing 50 µl of Carbolink coupling 
agarose gel (Thermo Scientific). The samples were incubated with beads for 10 minutes 
and centrifuged at 2,300 x g for 30 seconds to remove the flowthrough. The gel was 
washed with 200 µl portions of loading buffer, twice with washing buffer (100 mM acetic 
acid, 1% trifluoro acetic acid, 80% acetonitrile) and once with water. Then the 
phosphopeptides were eluted off the gel-bound PolyMAC-Zr by incubating twice with 
100 µl portions of 400 mM ammonium hydroxide solution. During washing and elution, 
each incubation step was carried out for 5 minutes with shaking. PolyMAC-Ti 
enrichment was carried out in a similar fashion, as described before26. 
 
 
2.2.4 Growing DG75 Cell Lysates in SILAC “Heavy” and “Light” Media 
For SILAC experiments, cells were grown to 50% confluency in SILAC RPMI-
1640 media (Gibco) substituted with 10% dialized inactivated FBS (Sigma-Aldrich), 1% 
sodium pyruvate, 0.5% streptomycin/penicillin, 0.05% β-mercaptoethanol, and either L-
Lysine and L-Arginine for “light” samples, or 13C6-Arginine and 
13C6-Lysine (Isotec) for 
“heavy” samples in 5% CO2 at 37ºC. Cells were grown for at least 6 divisions to ensure 
complete incorporation of the “heavy” amino acids (confirmed by mass spectrometry 
analysis; data not shown). Before each set of experiments, “light” and “heavy” cells were 










2.2.5 Piceatannol Treatment and Igm Pathway Stimulation 
The cell cultures were collected separately, washed with PBS and resuspended in 
PBS to obtain a cell density of 2 x 107 cells per milliliter, followed by treatment with 
piceatannol at the concentration of 50 µg per milliliter. Then the cells were incubated at 
37oC for 30 minutes. The B cell receptor signaling pathway was stimulated by treating 
the cells with the anti-IgM antibody at a concentration of 10 µL per milliliter and 
incubated at 4oC for 15 minutes. Finally, the cells were washed with PBS, collected, and 
frozen at -80 °C.  
 
2.2.6 Sample Fractionation and Phosphopeptide Enrichment 
Cells were lysed, protein content extracted, and the concentration was determined 
using the BCA assay as described above. Then, 2.5 mg samples of “heavy” and “light” 
labeled protein preparations were normalized mixed and digested with trypsin. The 
peptide sample was injected into Agilent 1100 HPLC system and separated either using 
4.6 mm x 150 mm XBridge BEH C18, 3.5 µm particle Reverse Phase Liquid 
Chromatography (RPLC)  column (Waters) or 4.6 mm x 200 mm Polyhydroxyethyl A, 
5µm particle Hydrophilic Interaction Chromatography (HILIC)  column (PolyLC Inc.). 
For the HILIC fractionation, the 5 mg peptide sample was dissolved in 2 ml of solvent B 
(0.1% formic acid in acetonitrile) and the sample was injected in 90% solvent B at a flow 
rate of 0.1 mL/min. Solvent A consisted of 0.1% formic acid in water. After loading the 
sample onto the column, it was washed with 90% solvent B for 15 minutes at 0.5 ml/min 
flow rate. Peptides were eluted in 85% B to 65% B gradient in 40 minutes followed by 





fractionation, the 5 mg peptide sample was dissolved in 4 mL of solvent A (10mM 
TMAB in water, pH 8) and the sample was injected in 98% solvent A at a flow rate of 0.5 
ml/min. After loading the sample onto the column, it was washed with 98% solvent A for 
10 minutes at 1 ml/min flow rate. Peptides were eluted over 98% A to 60% A gradient in 
60 minutes at 0.5 ml/min flow rate (solvent B used for elution was 10mM TMAB in 
acetonitrile, pH 8). For each separation, twenty fractions were collected. For the two sets 
of RPLC fractions, phosphopeptide enrichment was carried out with PolyMAC-Zr and 
PolyMAC-Ti, whereas the phosphopeptides in HILIC fractions were enriched only with 
PolyMAC-Zr.  
 
2.2.7 LTQ-Orbitrap Analysis 
Peptide samples were redissolved in 10 µl of 0.25% formic acid and injected into 
the Eksigent nano LC Ultra 2D system. The reverse phase C18 was performed using an 
in-house C-18 capillary column packed with 5 µm C18 Magic bead resin (Michrom; 75 
µm i.d. and 12 cm of bed length). The mobile phase buffer consisted of 0.1% formic acid 
in ultra-pure water with the elution buffer of 0.1% formic acid in 100% CH3CN run over 
a shallow linear gradient (from 2% CH3CN to 35% CH3CN) over 90 min with a flow rate 
of 300 nl/min. The electrospray ionization emitter tip was generated on the packed 
column with a laser puller (Model P-2000, Sutter Instrument Co.). The Eksigent Ultra 2D 
HPLC system was coupled with a hybrid linear ion trap Orbitrap mass spectrometer 
(LTQ-Orbitrap Velos; Thermo Fisher). The mass spectrometer was operated in the data-
dependent mode in which a full scan MS (from m/z 300 – 1700 with the resolution of 





scans were used) of the most abundant ions. Ions with charge state of +1 or undetermined 
charge states were excluded.  The mass exclusion time was 90 s.  
 
 
2.2.8 Database Search 
The LTQ-Orbitrap raw files were searched directly against human database using 
SEQUEST or MASCOT on Proteome Discoverer (Version 1.3, Thermo Fisher). 
Proteome Discoverer created DTA files from raw data files with minimum ion threshold 
15 and absolute intensity threshold 50. Peptide precursor mass tolerance was set to 10 
ppm, and MS/MS tolerance was set to 0.8 Da. Search criteria included a static 
modification of cysteine residues of +57.0214 Da and a variable modification of 
+15.9949 Da to include potential oxidation of methionine and a modification of +79.996 
Da on serine, threonine or tyrosine for the identification of phosphorylation. Searches 
were performed with full tryptic digestion and allowed a maximum of two missed 
cleavages on the peptides analyzed from the sequence database. False discovery rates 
(FDR) were set to 1% for each analysis. Proteome discoverer generates a reverse “decoy” 
database from the same protein database and any peptide passing the initial filtering 
parameters that were derived from the decoy database is defined as false positive 
identification. The minimum cross-correlation factor (Xcorr) filter was readjusted for 
each individual charge state separately in order to optimally meet predominant target 
FDR of 1% based on the number of random false-positive matches from the reverse 
“decoy” database. Thus, each dataset had its own passing parameters. The number of 
unique phosphopeptides and non-phosphopeptides identified were then counted using in-





determined by PhosphoRS on Proteome Discoverer 1.3.  For SILAC experiments, in 
addition to the above parameters, a dynamic modification of +6.020 Da was added on 
arginine and lysine. The quantification method was set to SILAC 2plex (Arg6, Lys6) and 
Light/Heavy ratios were reported.  
 
 
2.2.9 Data Analysis 
A list of all phosphopeptides identified in different fractions was prepared and 
unique peptides were extracted based on the m/z value and the charge state using in-
house software. The phosphosite localizations were obtained from PhosphoRS 
assignments.  If the same peptide sequence appears more than once in this list with 
different light/heavy ratios, the average ratio was calculated and assigned for that 
particular sequence. The mean and the standard deviation were calculated for the non-
phosphorylated peptides and the cut off values for phosphopeptides were determined by 
considering the 2x the standard deviation from this mean. In order to predict upstream 
kinases for identified phosphosites, an in-house software utilizing the kinase motifs listed 
on human protein reference database was used. 
 
2.2.10 Pathway Analysis 
A list of proteins corresponding to peptides showing significantly increased or 
decreased phosphorylation was extracted. This list with decreased and increased 
phosphorylation and the corresponding SILAC ratios were submitted to Ingenuity 





known human cellular proteins and their direct interactions. In addition, protein functions 
were predicted using DAVID bioinformatics tool.  
 
2.2.11 Cell Culture and Biological Reagents for Ubiquitination Study 
DT40 B cell lines were grown to a density of 0.4 x 106 cells/mL in RPMI-1640 
medium containing 7.5% FBS, 1% chicken serum, 100 U/mL penicillin, 100 mg/mL 
streptomycin and 50µM 2-ME.  For cell stimulation, phorbol 12-myristate-13-acetate 
(PMA) was used (Sigma-Aldrich).  For immunoblotting, anti-Syk (N-19) and anti-
ubiquitin (P4D1) were purchased from Santa Cruz Biotechnology.  Anti-GAPDH was 
purchased from Ambion.   
 
2.2.12 Ubiquitination Assay 
DG75 cells in RPMI 1640 media were treated with 5 µM MG132 for 3 hours in 
an incubator at 37oC, washed and resuspended in PBS. The cells were divided into four 
groups; two were treated with piceatannol at a concentration of 50 µg/mL and the other 
two were treated with DMSO control by incubating in a 37 oC water bath for 30 minutes. 
One set from each treatment group was stimulated with anti-IgM antibody for 15 minutes 
on ice. Cells were washed with PBS and pellets were prepared. Cell pellets were lysed 
using a solution containing 1% Noindent P-40, 50mM Tris-Cl pH 8.0, 100mM NaCl, 
5mM EDTA, 1mM NaVO3, 10mM NaF, 1x phosphatase inhibitor cocktail (Sigma-
Aldrich), and 1x mammalian protease inhibitor cocktail (Sigma-Aldrich).  Proteins were 





Flag-tagged ubiquitin was over-expressed in Syk-EGFP-expressing or Syk-
negative DT40 chicken B cells.  Cells were then treated with 100ng/mL PMA or DMSO 
for the indicated times.  Cells were lysed using a solution containing 1% Noindent P-40, 
50mM Tris-Cl pH 8.0, 100mM NaCl, 5mM EDTA, 1mM NaVO3, 10mM NaF, 20 mM 
N-ethylmaleimide, 1x phosphatase inhibitor cocktail (Sigma-Aldrich) , and 1x 
mammalian protease inhibitor cocktail (Sigma-Aldrich).  Proteins were separated using 
SDS-PAGE and protein ubiquitination was measured via Western blot.  
 
2.2.13 Immunoblotting of Ubiquitination 
For immunoblotting, membranes were blocked in 5% goat serum for 1hr.  All 
primary antibodies were incubated for 1 hour at room temperature and visualized using 
an HRP-conjugated secondary antibody and ECL reagents.     
 
2.2.14 LC-MS/MS Analysis of Ubiquitination 
DG75 cells were cultured, treated with MG132 and divided into two groups. One 
group was treated with piceatannol as detailed above and the other group was treated with 
DMSO control. The protein content was extracted and 40 mg portions were digested as 
detailed before; chloroacetamide was used in place of ioadoacetamide. Ubiquitinated 
peptides were enriched using UbiScan ubiquitin remnant antibody kit (Cell Signaling 
Technology) according to manufacturer’s protocol, and the LC-MS analysis was carried 






2.3 Results and Discussion 
 
2.3.1 Polymac-Zr for Phosphopeptide Enrichment 
We  introduced recently PolyMAC-Ti for efficient capturing of 
phosphopeptides26. In addition to titanium, zirconium is capable of effectively binding to 
phosphate groups, and this property has been successfully explored for both 
phosphopeptide enrichment19, 29 and DNA capturing30, 31 using solid supports. To further 
explore the utilization of zirconium ion for phosphopeptide enrichment, we developed a 
soluble nanopolymer-based reagent, PolyMAC-Zr (Figure 2.3.1), polyamidoamine 
(PAMAM) generation 4 dendrimer functionalized with Zr4+ ions. Hydroxylamine groups 
were attached to the dendrimer, which were used as the “handle” to capture the 
dendrimer onto aldehyde-functionalized agarose beads through a rapid covalent reaction. 
During phosphopeptide enrichment, a complex peptide mixture is incubated with the 
PolyMAC-Zr reagent in solution, resulting in the rapid and selective binding of 
phosphopeptides in the homogenous solution. The phophopeptide-bound PolyMAC-Zr 
reagent is then isolated using the aldehyde-functionalized beads. Lastly, the bound 
phosphopeptides are eluted off under basic conditions for mass spectrometric analysis. 
The capability of the reagent to effectively enrich phosphopeptides was first evaluated 
using a simple mixture containing angiotensin II and phosphorylated angiotensin II 
(Figure 2.3.2), and then with a panel  of peptides  generated from phosphorylated ( α-
casein, β-casein and ovalbumin) and unphosphorylated proteins (lactalbumin, β-





majority of peaks detected by MALDI-TOF analysis were non-phosphopeptides. After 
the enrichment, only phosphopeptides were observed (Figure 2.3.3). 
To evaluate the performance of the new reagent for use in a complex mixture, we 
further tested it with a whole cell lysate generated from the human Burkitt’s lymphoma B 
cell line, DG75. A 100 µg sample of the cell lysate was digested with trypsin and 
subjected to phosphopeptide enrichment by PolyMAC-Zr. Among the various tested 
loading buffer conditions, a solution consisting of 200 mM glycolic acid, 50% 
acetonitrile and 1% trifluoroacetic acid was optimal for high selectivity and recovery. 
The PolyMAC-Zr reagent captured over 1,200 unique phosphopeptides from 100 µg of 
DG75 cell lysate with over 60% selectivity for phosphorylated peptides (Figure 2.3.4 a, 
b). The overlap of identified phosphopeptides between any two experiments was 
approximately 75%, demonstrating the excellent reproducibility of homogeneous capture 
with PolyMAC-Zr (Figure 2.3.4 c), consistent with previous studies with PolyMAC-Ti26. 
On the other hand, the overlap of phosphopeptides enriched by PolyMAC-Zr and 
PolyMAC-Ti was less than 50% (Figure 1d), indicating each metal ion enriched a unique 
set of phosphopeptides. 
 
2.3.2 In-Depth Analyses of Syk-Dependent Phosphorylation in B-Cells 
PolyMAC-Zr was used in combination with PolyMAC-Ti to investigate Syk-
dependent phosphorylation in B cells following anti-IgM stimulation of the BCR (Figure 
2.3.5). Two populations of DG75 cells were grown in SILAC media containing either 
“light” or “heavy” (13C6-labeled) arginine and lysine. One group of cells was treated with 





Both sets were stimulated with anti-IgM antibody to activate the BCR signaling pathway.  
Equal amount of protein (2.5 mg) extracted from each cell population were mixed and 
digested with trypsin.  
In order to reduce the sample complexity we used RPLC32 or HILIC25 in the first 
dimension of peptide fractionation.  HILIC and RPLC are complementary separation 
methods25, 33 and we used PolyMAC-Zr to enrich phosphopeptides after HILIC fractions.  
The orthogonality of RPLC was achieved by separating peptides at high (pH 8) and low 
pH (pH 2.6) values in the two dimensions32, 34.  Previously this has been successfully 
applied for both phosphopeptide and non-phosphopeptide separations32, 34, 35. Each RPLC 
fraction was enriched for phosphopeptides using PolyMAC-Zr or PolyMAC-Ti before the 
LC-MS/MS analysis. Figure 2.3.6 summarizes the total number of phosphopeptides, the 
number of unique phosphopeptides obtained from each fractionation approach and the 
distribution of phosphopeptides in different fractions. As expected, the unique 
phosphopeptides identified using PolyMAC-Zr versus PolyMAC-Ti demonstrated only 
about 50% overlap (Figure 2.3.6.b). A total of 13,029 unique phosphopeptides 
representing over 16,000 unique phosphorylation sites were identified in this study.  The 
distribution of serine, threonine and tyrosine phosphosites is illustrated in Figure 2.3.6 c. 
The relative abundances of 0.05%, 10% and 90% have been reported for 
phosphotyrosine, phosphothreonine and phosphoserine, respectively. Here we identified 
437 (2.6%) phosphotyrosine, 2447 (15.1%) phosphothreonine and 13304 (82.2%) 
phosphoserine sites. The relative abundances are close to expected values for 
phosphothreonine and phosphoserine but significantly higher for phosphotyrosine. Such 





enable identification of low abundant proteins that are usually phosphorylated on tyrosine 
residues10. We compared quantitatively the “light” to “heavy” ratios of identified 
phosphopeptides between the piceatannol-treated and untreated samples to assess the 
importance of Syk to BCR-stimulated phosphorylation. Out of 13,029 unique 
phosphopeptides, 1,506 showed more than a 2-fold increase, whereas 2,340 showed more 
than a 2-fold decrease by treatment with the inhibitor. These unique phosphopeptides 
provided a list of 1,982 phosphorylation sites with increased phosphorylation from 1,049 
proteins and 2,960 sites with decreased phosphorylation levels from 1,446 proteins.  
 
2.3.3 Regulation of Cellular Functions by Syk Dependent Phosphorylation 
In the presence of an antigen, B cell receptor (BCR) aggregates and transduces 
signals to the cell interior by activating Src-family kinases Lyn, Blk and Fyn, as well as  
tyrosine kinases Syk and BTK. These participate in signaling complexes that include 
adaptor proteins such as CD19 and BLNK and signaling effectors such as PLC, PI3K 
and VAV. Signals transduced through these components activate multiple downstream 
signaling cascades, inducing changes in cellular metabolism, gene expression and 
cytoskeletal organization. These signaling cascades can regulate survival, tolerance, 
proliferation, or differentiation of B cells2, 36, 37. Therefore, it is important to understand 
the Syk-dependent processes of these complicated signaling events. Elucidation of these 
processes can be facilitated by examining signaling events with and without the inhibition 
of Syk using piceatannol. Proteins directly involved in these pathways typically 





loops and lack of activation of phosphatases may result in increased levels of 
phosphorylation in some proteins36-38.  
To further understand the Syk-dependent changes in phosphorylation, the nature 
of upstream kinases were predicted based on the sequences of phosphorylation sites  
using software developed in-house, as shown in Figure 2.3.7 a. A list of kinase motifs 
was extracted from the human protein reference database (HPRD)39, and upstream 
kinases were predicted for all the phosphorylation sites identified with changing 
phosphorylation levels. The normalized fraction of phosphorylation sites for each kinase 
is illustrated in Figure 2.3.7 a, where a positive value indicates the fraction of 
phosphorylation sites with increased phosphorylation and a negative value indicates the 
fraction of phosphorylation sites with decreased phosphorylation upon treatment with 
piceatannol.  According to the above analysis, calmodulin-dependent kinase motifs are 
found only among the sites with decreased phosphorylation. Intracellular calcium levels 
increase during BCR signaling1 and Syk inhibition interrupts proper signal propagation,40 
which may lead to the decreased activity of calcium dependent kinases. AKT and NIMA 
kinase motifs are represented only among sites with increased phosphorylation. AKT is 
activated downstream of BCR engagement in B cells; therefore, a decrease in AKT 
activity is expected upon Syk inhibition. However, this observed increase in 
phosphorylation could be due to the fact that most cultured lymphoid cell lines, including 
DG75, lack both PTEN and SHIP1 and have constitutively active Akt41-43. Furthermore, 
there are significantly higher numbers of CDC-like kinase 1 (CLK1) and AMP-activated 
protein kinase (AMPK) with decreased phosphorylation. AMPK is known to be activated 





LAT and SLP7644. CLK1 is a dual specificity kinase expressed in the nucleus that is 
involved in mRNA splicing45. Serine/arginine rich proteins are known substrates for this 
kinase46, and several such proteins show decreased phosphorylation levels in our study. 
Interestingly, we identified RNA post-transcriptional modifications pathway as one of the 
perturbed networks upon Syk inhibition (Figure 2.3.7 b, and Figure 2.3.8 a). Specifically, 
mRNA spicing factors, ribonuclear proteins and splicing regulatory proteins show 
significant changes in levels of phosphorylation.  
Interestingly, Src-family kinases, polo-like kinase 1(PLK1), and ataxia 
telangiectasia mutated kinase (ATM) substrate sites are enriched among sites with 
increased phosphorylation. Syk and Src family kinases are known to participate in 
signaling cross talk47 and may have non-redundant48 or opposing49 roles in some 
pathways. Therefore, Syk inhibition may have affected cross talk between Syk and Src 
kinases resulting in increased levels of Src family kinase-dependent phosphorylation. 
PLK1, on the other hand, functions in centrosome maturation, spindle assembly and 
cytokinesis. Prior experiments have revealed autophosphorylation-dependent centrosomal 
localization of Syk4, 6, 50 and co-localization of Syk and PLK1 at mitotic spindle poles51. 
Threonine phosphorylation on Syk by PLK1 has been reported to be a part of an anti-
apoptotic mechanism, and the disruption of the mechanism may have activated 
alternative PLK1-dependent phosphorylation events51.  Furthermore, we have identified 
centrosome organization as one of the functions perturbed upon Syk inhibition (Figure 
2.3.7 b and Figure 2.3.8 b). 
A limitation in upstream kinase prediction is the lack of known consensus 





enzymes. Furthermore, the substrate specificities of many kinases overlap, making it 
difficult to attribute specific phosphorylation events to a single kinase.  Still, some of the 
kinase motifs show significant enrichment among groups of sites with distinctive higher 
or lower phosphorylation levels. On the other hand, functional annotation provides 
complementary information that can be correlated with phosphorylation changes of 
kinase specific sites. For example, we have identified NPM1, NUDC and BUB1B which 
are PLK1 substrates during centrosome organization. Therefore it is likely that these 
kinases are acting as nodes in various downstream pathways that are modulated by Syk in 
B cells. Some of the important pathways and functions are summarized in Figure 2.3.7 b. 
The function of Syk in the immune system has been widely studied52 and we observed 
the B cell receptor (BCR) signaling pathway as the most perturbed canonical pathway 
(Figure 2.3.9). Furthermore, other known Syk-dependent networks such as FcRIIB, 
PI3K, PLC signaling, NFAT regulation2 and centrosome organization were also 
observed. More interestingly, we identified RNA post transcriptional modification and 
the ubiquitin proteasome pathway as novel potential Syk-dependent pathways.    
 
2.3.4 Syk-Dependent Ubiquitination in B-cells 
One of the most intriguing networks in our data annotation is the ubiquitin 
proteasome pathway (Figure 2.3.10). We identified and quantified a significant number 
of phosphorylated nodes that function in this pathway, including E1, E2, E3 ligases, 
proteasome components, and deubiquitinases (DUBs). The proteins belonging to the 
above categories are summarized in Figure 2.3.11 a with the SILAC fold change ratios 





proteasome pathway identified in this study, DUBs are the most prominent group. The 
majority of DUBs were found to contain significantly decreased levels of 
phosphorylation on one or more sites after Syk inhibition, such as Y364 on ubiquitin 
specific peptidase 10 (USP10). Deubiquitinases are tightly regulated both spatially and 
temporally, similar to ubiquitin ligases, thus enabling careful control over cellular 
signaling and protein stability53. Phosphorylation is thought to be a key regulatory 
mechanism for DUBs, as was demonstrated by a recent study of the human 
deubiquitinase DUBA being controlled through phosphorylation at S177 by casein kinase 
(CK2)54 and USP25 has been reported as a Syk substrate55. This is the first report on the 
regulation of ubiquitination by Syk.  
 
2.3.5 Proteomics Analysis of Syk-dependent Ubiquitination 
In order to identify ubiquitinated proteins modulated by Syk, DG75 cells were 
treated with MG132 to inhibit the proteasome and half of the cells were also treated with 
piceatannol to inhibit the Syk activity. An examination of global protein ubiquitination by 
western blot analysis showed a substantial decrease in protein ubiquitination following 
the treatment of cells with piceatannol (Fig. 2.3.11 b). After cell lysis and protein 
digestion, the ubiquitinated peptides were enriched using an antibody raised against the 
di-glycine motif, and the resulting peptides were identified using LC-MS/MS. 
Quantification was achieved in a label-free manner using a synthetic peptide library56.  
This examination resulted in the identification and quantification of over 1,300 unique 
ubiquitination sites. Although the overall level of ubiquitination was increased, after 





we found that 360 and 520 peptides showed decreased and increased ubiquitination 
representing 282 and 372 proteins, respectively. It should be noted that anti-ubiquitin 
antibody used for Western blots shows stronger signals for polyubiquitinated proteins 
whereas antibody against diglycine residue does not distinguish between mono and 
polyubiquitination. Hence the ubiquitin proteomics experiment may not perfectly match 
the Western blot results. Our goal was to specifically identify proteins with decreased 
ubiquitination upon Syk inhibition. A functional annotation was carried out for the 
proteins with increased or decreased ubiquitination. IPA analyses revealed that the 
proteins with functions in RNA post transcriptional modifications and nucleic acid 
metabolism are prominent among proteins with decreased ubiquitination, illustrated in 
figures 2.3.12 a and b respectively. For example, Pre-mRNA-processing-splicing factor 8 
(PRPF8), heterogeneous nuclear ribonucleoprotein H3 (HNRNPH3), RNA-binding 
protein 39 (RBM39) and U2 small nuclear ribonucleoprotein B (SNRPB2) are among 
proteins functioning in RNA post transcriptional regulation specifically by RNA 








Previous studies on Syk-dependent signaling events in B cells focused mainly on 
tyrosine phosphorylation, thus limiting information on potentially diverse Syk functions 
and downstream signaling events. With Syk being an upstream kinase within several 
signaling cascades, there are numerous opportunities for serine/threonine phosphorylation 
events that can be modulated by its kinase activity. Our integrated approach of using 
complementary Ti- and Zr-based phosphopeptide enrichment with RPLC and HILIC 
fractionation has led to identification of over 16,000 unique phosphorylation sites and 
quantification of nearly 4,000 peptides with significant phosphorylation changes. The 
annotation of corresponding proteins reiterated known Syk-dependent functions and 
suggested novel potential networks. Furthermore, canonical pathway analysis suggested a 
significant influence of Syk activity on ubiquitination network in B cells. The subsequent 
examination of the dependence of ubiquitination on Syk activity was carried out and 
among more than 1,300 ubiquitination sites identified, the data showed decreased 
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Figure 2.2: Evaluation of PolyMAC-Zr Using a Simple Peptide Mixture. A peptide mixture 
containing angiotensin II (m/z 1046) and phosphangiotensin II (m/z 1126) was enriched 
with PolyMAC-Zr and analyzed by matrix assisted laser desorption ionization (MALDI) 
time of flight (TOF)/TOF mass spectrometry. The peptide mixture before enrichment (a), 
elution after enrichment (b), and the initial amount of angiotensin II (m/z 1046) spiked 







Figure 2.3: Evaluation of the Selectivity of PolyMAC-Zr. Using a mixture of trypsin-
digested α-casein, β-casein and ovalbumin (phosphoproteins), α-lactalbumin, β-
lactoglobulin, catalase, hemoglobin and bovine serum albumin (non-phosphoproteins). 
The peptide mixture was enriched with PolyMAC-Zr and analyzed by matrix assisted 
laser desorption ionization (MALDI) time of flight (TOF)/TOF mass spectrometry. (a) 
Before enrichment, and with different phosphopeptide enrichment “enhancers” in the 
loading buffer (b) 300 mM glycolic acid, (c) 100 mM glycolic acid, (d) 100 mM formic 
acid, (e) 300 mM latic acid (f) 100 mM lactic acid, (g) 100 mM citric acid, (h) 200 mM 
3-hydroxypropanoic acid. Evaluation of PolyMAC-Zr using digests of DG75 cell lysates. 
(i) Comparison of three phosphopeptide enrichment experiments showing the number of 
phosphopeptides enriched in each experiment and the number of non-phosphopeptides 
identified in each experiment. (j) Comparison of PolyMAC-Zr and PolyMAC-Ti for the 
number of phosphopeptides enriched and the selectivity. (k) Overlap of phosphopeptide 
enrichment between any two PolyMAC-Zr experiments or PolyMAC-Zr and PolyMAC-












Figure 2.4: Evaluation of PolyMAC-Zr 
Using DG75 Cell Lysates. (a) 
Comparison of three PolyMAC-Zr 
phosphopeptide enrichment 
experiments showing the number of 
phosphopeptides enriched in each 
experiment and the number of non-
phosphopeptides identified in each 
experiment. (b) Comparison of 
PolyMAC-Zr and PolyMAC-Ti for the 
number of phosphopeptides enriched 
and the selectivity. (c) Phosphopeptide 
identification overlap of 
phosphopeptide enrichment between 
any two PolyMAC-Zr experiments or 




























































Figure 2.6: The Summary of 
B-Cell Phosphopeptide 
Fractionation and Enrichment. 
(a) Overall phosphopeptide 
identification in each 
separation-enrichment 
combinations. Total number of 
phosphopeptides was 
calculated by adding the 
number of phosphopeptides in 
each fraction and the unique 
phosphopeptides were 
calculated by removing any 
duplicate identification. (b) 
The number of 
phosphopeptides identified in 
each fraction in three 
separation and enrichment 
combinations. RPLC and 
HILIC fractions enriched by 
PolyMAC-Zr, and RPLC 
fractions enriched by 
PolyMAC-Ti. (c)  Upper panel 
shows the phosphopeptide 
overlap of RPLC fractions 
enriched with PolyMAC-Ti 
and PolyMAC-Zr. Lower 
panel shows the overlap 
between RPLC and HILIC 
fractions both enriched with 
PolyMAC-Zr. (d) The pie 
chart shows the percentages of 
serine, threonine and tyrosine 
phosphosites identified in this 
study. 
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Figure 2.9: B-cell Receptor Signaling Pathway and Phosphoproteins Perturbed by Syk 
Inhibition. The color scheme red to green indicates phosphorylation increase and 








Figure 2.10: Protein Ubiquitination Pathway. The color scheme red to green indicates 
phosphorylation increase and decrease respectively.  
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CHAPTER 3: SEQUENTIAL ENRICHMENT OF TYROSINE PHOSPHOPEPTIDES 
 
3.1 Introduction 
B cells are an important entity of the adaptive immune system and they are 
characterized by the presence of the surface immunoglobulin known as the B cell 
receptor (BCR) which is capable of recognizing a diverse range of foreign antigens1. The 
activation of B cells through cross-linking of BCR by antigen engagement initiates 
phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs). 
According to current knowledge the tyrosine kinase, Syk and the Src-family kinase, Lyn 
are the first molecules recruited to form this singling complex1, 2. In addition to Lyn and 
Syk numerous adaptor proteins and effector proteins such as phospholipase C- (PLC),  
phosphatidylinositide 3-kinase (PI3K), guanine nucleotide exchange factor Vav and B-
cell linker protein (BLNK)  are vital components in signaling complexes in B cell2.  Thus 
formed complex elicit many downstream pathways such as  activation of Btk, 
mobilization of  Ca2+ ions and activation of NFAT pathway, PI3K, Akt and mTOR 
pathways, Ras/MEK/ERK pathway and activation of NF-B  through protein kinase C 
(PKC), CARMA1, BCL10, and MALT11-4. It is well accepted that the tyrosine kinase 
Syk and the Src family kinase, Lyn are at the top of these signaling cascades and there are 





Initially the signaling function of Syk was considered to be limited to 
immunoreceptors of the adaptive immune system. However more recent discoveries have 
reported Syk mediated signaling by the collagen receptor glycoprotein VI5, integrins6 and 
C type lectins7 as well as roles for Syk in lymphatic vascular development8 and born 
resorption by osteoclasts9 providing evidence for diverse functionality of Syk in cellular 
environment extending beyond adaptive immune system. Lyn, on the other hand, is a Src 
family member predominantly expressed in hematopoietic cells and known for its dual 
activity in positively and negatively regulating cellular signaling10-12. In B cells, Lyn 
phosphorylates several ITIM-containing inhibitory receptors, such as CD22 and Fc 
receptor gamma IIb (FcγRIIb)12.  Also it interacts with tyrosine phosphatases such as 
SHP-1, SHP-2 or the inositol phosphatase SHIP-1 required to down regulate BCR 
signaling12-14. Similar to Syk, Lyn also acts downstream of many other receptors such as 
GM-CSF receptor15, FceRI16, Epo receptor17-19, c-kit20 and integrins21  in both positive 
and negative regulatory functions.  
One of the earliest events in BCR stimulation is the induction of tyrosine kinases. 
It has been demonstrated that Syk deficient and Lyn deficient B cells have different 
patterns of phosphorylation indicating that Syk and Lyn mediate different signaling 
pathways after BCR stimulation22. This suggests that Syk and Lyn have distinct functions 
and different sets of substrates. There are numerous reports detailing complementary and 
opposing functions of Syk and Lyn in cellular pathways. For example, in  Syk negative B 
cells tyrosine phosphorylation on PLC was abolished resulting loss of both inositol 
1,4,5-trisphosphate (IP3) generation and Ca2+ immobilization following BCR stimulation 





concentration has been observed22 showing that both these kinases have some role in the 
process. Although the Ca2+ ion increase is slow in Lyn deficient cells, it is amplified and 
prolonged and B cells from Lyn deficient mice are hyper-responsive to IgM cross-linking 
leading to hyper-activation of ERK1, ERK2, MEK1 and c-Jun N terminal kinase and 
show a hyper-proliferation response suggesting an inhibitory effect on BCR signaling by 
Lyn. The negative regulatory effect of Lyn on BCR signaling is exerted in several 
different ways. Upon BCR stimulation, kinases are recruited to the cross-linking site on 
the plasma membrane and Syk becomes phosphorylated on Y317, Y342 and Y346 
located in the linker region23.  Phosphorylation on Y317 on Syk by Lyn strongly reduces 
Ca2+ immobilization through PI-3K dependent pathway in a negative regulatory 
mechanism23, 24. After BCR stimulation, Syk-receptor complex aggregates as patches on 
the membrane and forms a cap at one pole of the cell. Syk is essential for the formation 
and stabilization of tightly capped BCR complex at the plasma membrane. In the absence 
of Lyn, Syk is still recruited to the cross-linked receptor but the receptor internalization is 
impaired resulting a long-lived receptor-Syk complex at the plasma leading to prolonged 
signaling25. Furthermore, the activation of AKT is regulated by Syk after BCR cross-
linking and in Lyn deficient B-cells, AKT shows hyper-phosphorylation and enhanced 
activity indicating opposing effects of Syk and Lyn on AKT activation26. The drug 
sensitive CML cells acquire resistance to nilotinib upon coexpression of Syk and Lyn. 
Lyn mediates the drug resistance through phosphorylation of Syk and Axl , on the other 
hand, Syk mediates the drug resistance through phosphorylation of Lyn and Axl 
indicating the complementary behavior of Lyn and Syk during CML cell drug 





and Lyn during BCR signaling as well as in other processes. Further it can be assumed 
that with the diverse range of signaling processes that these two kinases participate, 
similar roles in other receptor signaling events also.  
This study was designed to further investigate the roles of Syk and Lyn in B-cells 
at the proteomics level. In order to do that DT40 wild type, Syk deficient, Lyn deficient 
and Syk and Lyn deficient cell lines were used. Phosphotyrosine peptides were enriched 
in a sequential approach where in the first step the peptides were enriched with tyrosine 
specific antibody beads and in the second step those peptides were re-enriched with 
PolyMAC-Ti. Over 1000 phosphotyrosine sites were identified in this approach and 
depending on the phosphorylation changes across the different samples the sites were 
categorized into five different categories. Further analysis of these categories reaffirmed 
known Syk and Lyn dependent cellular functions as well as suggested novel functions 









3.2.1 Isolation of Tyrosine Phosphopeptides from DG75 Cells  
DG-75 cell culture was grown to 80% confluence in RPMI-1460 media 
substituted with 10% inactivated FBS, 1% sodium pyruvate, 0.5% 
streptomycin/penicillin, and 0.05% β-mercaptoethanol. Then the cells were washed with 
PBS, collected, and frozen at -80 °C. Cells were lysed in 1 mL of lysis solution (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1x 
phosphatase inhibitor cocktail (Sigma-Aldrich), 10 mM sodium fluoride) with sonication. 
The resulting mixture was centrifuged at 16,100 × g for 10 minutes, and supernatant 
containing soluble proteins was collected. The protein concentration was measured using 
the BCA assay. DG-75 protein lysate was denatured and reduced in 50 mM trimethyl 
ammounium bicarbonate containing 0.1% RapiGest (Waters) and 5 mM dithiothreitol for 
30 minutes at 50 °C. The proteins were further alkylated in 20 mM iodoacetamide for 1 
hour in the dark at room temperature, and digested with proteomics grade trypsin at 1:100 
ratio overnight at 37 °C. The pH was adjusted below 3 and the sample was incubated for 
40 minutes at 37 °C. The sample was centrifuged at 16,100 × g and supernatant was 
collected. The sample was desalted with a Sep-Pak C18 column (Waters). The 
enrichment of phosphopeptides was carried out using 100 µg samples, according to the 








3.2.2 Enrichment of Tyrosine Phosphopeptides Using Anti-Phosphotyrosine Beads 
 
The required amount of peptide sample was taken and dissolved in Tris-Cl pH 7.5 
buffer and anti-phosphotyrosine antibody beads (PT66, Sigma-Aldrich) was added at a 
ratio of 40 µl of slurry for 1 mg of protein. The mixture was incubated at 4oC overnight 
with end-over-end rotation. The beads were washed with the lysis buffer twice and with 
water once at 4oC, then the phosphotyrosine peptides were eluted three times with 0.1% 
TFA and another three times with 0.1% TFA/50% acetonitrile mixture at room 
temperature. The eluents were dried used for the secondary enrichment with PolyMAC-
Ti.  
 
3.2.3 Enrichment of tyrosine Phosphopeptides Using PolyMAC-Ti 
The peptide mixture was dissolved in 200 µl of the loading buffer (0.1% 
trifluoroacetic acid and 50% acetonitrile), 5 nmol of PolyMAC-Ti was added to it and 
incubated for 5 minutes at room temperature. Then 100 µl of capture buffer (3 mM 
glycolic acid/300 mM HEPES buffer at pH 7.7) was added, to increase the pH above 6.3 
and transferred to a non-stick tube containing 50 ul of magnetic hydrazide beads 
(SIMAC). The sample was incubated for 10 minutes with shaking at room temperature 
and the supernatant was removed. The beads were washed with 200 µl portions of 
loading buffer and twice with washing buffer (100 mM acetic acid, 1% trifluoro acetic 
acid, 80% acetonitrile). Then the phosphopeptides were eluted from the bead-bound 
PolyMAC-Ti by incubating twice with 100 µl portions of 400 mM ammonium hydroxide 





out for 5 minutes with shaking. The samples were dried and used for LC-MS/MS 
analysis.  
 
3.2.4 Isolation of Tyrosine Phosphopeptides from DT40 Cell Lysate 
DT40 cell culture was grown to 80% confluence in RPMI-1460 media substituted 
with 10% inactivated FBS, 1% Chicken serum, 1% sodium pyruvate, 0.5% 
streptomycin/penicillin, and 0.05% β-mercaptoethanol. Then the cells were washed with 
PBS, collected, and frozen at -80 °C. Cells were lysed in 1 mL of lysis solution (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1x 
phosphatase inhibitor cocktail (Sigma-Aldrich), 10 mM sodium fluoride) with sonication. 
The resulting mixture was centrifuged at 16,100 × g for 10 minutes, and supernatant 
containing soluble proteins was collected. The protein concentration was measured using 
the BCA assay. The sample preparation for mass spectrometric analysis was carried out 
as described above. Phosphotyrosine peptides were isolated as described above using 5 













3.2.5 LC-MS/MS analysis 
Peptide samples were redissolved in 10 µl of 0.25% formic acid and injected into 
an Eksigent nano LC Ultra 2D system. The reverse phase C18 was performed using an 
in-house C18 capillary column packed with 5 µm C18 Magic bead resin (Michrom; 75 
µm i.d. and 30 cm of bed length). The mobile phase buffer consisted of 0.1% formic acid 
in ultra-pure water with the elution buffer of 0.1% formic acid in 100% CH3CN run over 
a shallow linear gradient (from 2% CH3CN to 35% CH3CN) over 60 min with a flow rate 
of 300 nl/min. The electrospray ionization emitter tip was generated on the packed 
column with a laser puller (Model P-2000, Sutter Instrument Co.). The Eksigent Ultra 2D 
HPLC system was coupled with a hybrid linear ion trap orbitrap mass spectrometer 
(LTQ-Orbitrap Velos; Thermo Fisher). The mass spectrometer was operated in the data 
dependent mode in which a full scan MS (from m/z 300 – 1700 with the resolution of 30, 
000 at m/z 400) was followed by 20 MS/MS of the most abundant ions. Ions with charge 
state +1 were excluded.  The mass exclusion time was 90 s.  
 
3.2.6 Database search 
The LTQ-Orbitrap raw files were searched directly against chicken database using 
SEQUEST or MASCOT on Proteome Discoverer (Version 1.3, Thermo Fisher). 
Proteome Discoverer created DTA files from raw data files with minimum ion threshold 
15 and absolute intensity threshold 50. Peptide precursor mass tolerance was set to 10 
ppm, and MS/MS tolerance was set to 0.8 Da. Search criteria included a static 
modification of cysteine residues of +57.0214 Da and a variable modification of 





on serine, threonine or tyrosine for the identification of phosphorylation. Searches were 
performed with full tryptic digestion and allowed a maximum of two missed cleavages on 
the peptides analyzed from the sequence database. False discovery rates (FDR) were set 
to 1% for each analysis. Proteome discoverer generates a reverse “decoy” database from 
the same protein database and any peptide passing the initial filtering parameters that 
were derived from the decoy database and define as false positive identification. The 
minimum cross correlation factor (Xcorr) filter was readjusted for each individual charge 
state separately in order to optimally meet predominant target FDR of 1% based on the 
number of random false-positive matches from the reveres “ decoy” database. Thus, each 
dataset had its own passing parameters. The number of unique phosphopeptides and non-
phosphopeptides identified were then counted using in-house software and compared. 
Phosphorylation site localization from CID spectra was determined by PhosphoRS on 
Proteome Discoverer 1.3.  For quantitation, the same raw files were searched against a 
database of a peptide library which was spiked into each sample before the LC-MS/MS 
run.  
 
3.2.7 Data Analysis and Quantification 
A list of all the phosphotyrosine peptides identified was prepared and unique 
peptides were extracted based on the m/z value and the charge state using an in-house 
software. The site localizations were obtained from PhosphoRS assignments. Each 
peptide list was normalized using the peptide library and a Log 2 ratio was expressed as 






3.2.8 Motif Analysis 
In order to predict upstream kinases for identified phosphotyrosine sites, in-house 




3.2.9 Pathway Analysis 
A list of proteins corresponding to peptides showing increased or decreased 
phosphorylation was extracted. This list with decreased and increased phosphorylation 
and the corresponding fold change ratios were submitted to Ingenuity Pathway Analysis 





3.3 Results and Discussion 
 
3.3.1 Development of Phosphotyrosine Peptide Enrichment Method 
Tyrosine phosphorylation represents less than 1% of cellular phosphorylation 
compared to serine and threonine posing a challenge in identification specifically in a 
large scale phosphorpteomics experiments. This problem is usually circumvented by 
employing anti-phosphotyrosine antibody based enrichment at protein or peptide level. 
Although antibodies can enrich phosphotyrosine peptides efficiently over phosphoserine 
and phosphothreonine, they capture a large number of non-phosphopeptides, as depicted 
in Figure 1 a, the selectivity towards phosphotyrosine peptides is about 30%. 
Phosphopeptides are generally difficult to analyze by mass spectrometry because they are 
negatively charged and the electrospray is generally performed in positive mode. Also 
phosphopeptides are not observed as intense peaks in the presence of nonphosphorylated 
peptides owing to ion suppression effect. Therefore further reducing the amount of non-
phosphopeptides in the sample improves the identification of phosphotyrosin peptides. 
Hence it is common practice to use anti-phosphotyrosine antibody and phosphopeptide 
enrichment in sequential manner to improve phosphotyrosine identification. We applied a 
PolyMAC-Ti based enrichment to the sample after phosphotyrosine antibody enrichment 
and this allowed us to significantly decrease the number of non-phosphopeptides and 
increase the selectivity towards tyrosine phosphorylated peptides to 80% without 
sacrificing the number of identifications but increasing the identification as the sample 





results this method was used to study tyrosine phosphorylation related to two major 
kinases Syk and Lyn in B cells using Chicken B cell line DT40.  
 
3.3.2 Syk and Lyn-based Tyrosine Phosphorylation in B-cells 
Tyrosine kinase Syk and Src family kinase Lyn are at the top of the signaling 
cascades in B-cells and activates many cellular pathways.  DT40 cell line derived from 
chicken B-cells and Syk, Lyn or double knock-out DT40 cell lines have been extensively 
used to investigate downstream pathways of these kinases. Most of the previous studies 
have been focused on understanding the tyrosine phosphorylation after BCR stimulation, 
but now it is known that these kinases are involved in many other signaling events as 
well. Therefore in this study was planned to understand the phosphorylation events of 
these kinases using a proteomics approach without restricting to BCR signaling. DT40 
wild type, Syk-/-, Lyn-/- and Syk-/-Lyn-/- cell lines were grown as detailed in previous 
reports, cells were collected and treated with sodium orthovanadate to inhibit 
phosphatases. The phosphatase inhibition is extensively used in studies related to 
phosphoryloation in B-cells, as the treatment inhibits phosphatases transient 
phosphorylation on substrate proteins can be preserved during the sample preparation 
which helps identification of these phosphorylation sites in the mass spectrometer. The 
cells were lysed, protein component was extracted, digested with trypsin and the sample 
was incubated with anti-phosphotyrosine antibody. The peptides eluted from the antibody 
beads were re-enriched with PolyMAC-Ti and a standard peptide library was spiked into 
each peptide sample for quantification during the LC-MS/MS analysis. DT40 wild type 





the wild type sample. The quantitative changes of each phosphotyrosine site were 
assessed across Syk, Lyn and double knockout cell lines.  Based on the quantifications 
the entire phosphotyrosine site list could be grouped into five major categories as shown 
in figure 3a as Syk dependent, Lyn dependent, Syk and Lyn dependent, Syk or Lyn 
dependent and Syk and Lyn independent. Phosphotyrosine sites that are grouped as Syk-
dependent showed decreased phosphorylation levels in Syk-/- DT40 cells and Syk-/-Lyn-
/- DT40 cells whereas increased or unchanged phosphorylation levels in Lyn-/- cells. 
Lyn-dependent showed decreased phosphorylation levels in Lyn-/- DT40 cells and Syk-/-
Lyn-/- DT40 cells whereas increased or unchanged phosphorylation levels in Syk-/- cells. 
Syk and Lyn-dependent sites showed decreased phosphorylation levels in both Syk-/- and 
Lyn-/- cells as well as double knock out cell line. Syk or Lyn dependent sites showed 
increased or unchanged phosphorylation levels in one of the cell lines and unchanged or 
decreased phosphorylation levels in Syk-/-, Lyn-/- double negative cell line. The sites that 
are not affected or showing increased phosphorylation levels with the loss of Syk and 
Lyn are grouped as Syk and Lyn independent. As shown in figure 3a there were 522 Syk-
dependent phosphotyrosine sites, 234 Lyn-dependent phosphotyrosine sites, 266 Syk and 
Lyn dependent sites, 58 Syk or Lyn dependent sites and 47 Syk and Lyn independent 
sites. This observation is comparable with the anti phosphotyrosine western blot of the 
cell lysates of the four cell lines used (Supplementary figure 1). Wild type cells show the 
highest amount of tyrosine phosphorylation and it is closely followed by the Lyn- cell 
line. This could be due to the loss of inhibitory effect of Lyn on Syk. Further supporting 





Syk double negative cells show extremely low phosphorylation levels on the western 
blot.  
 
3.3.3 Consensus Motif Analysis 
In order to further confirm Syk or Lyn dependency of these sites motif logos were 
generated for the peptides in each category and shown in figure 3b-f. Syk substrate motifs 
are characterized by acidic residues around the tyrosine site and the Lyn substrate motifs 
are characterized with a hydrophobic residue before the tyrosine and acidic residue after 
the tyrosine. (Supplementary figure 2) Direct Syk and Lyn substrate sites are expected to 
find in the Syk dependent and Lyn dependent data sets respectively. Syk-dependent sites 
generated EDEEDYEESEE as a prominent motif which is quite comparable with the 
accepted Syk motif EDEE(D/E)YEESEE. Lyn dependent site motifs showed 
EEEEA(I/L/V)YESLEKK as a prominent motif which is comparable with the accepted 
Lyn motif IYE. Syk and Lyn-dependent sites highlight (L/D/E)Y(D/E) with both acidic 
or hydrophobic residues at the phosphorylation motif indicating potential Syk or Lyn 
dependent site motif is much closer to Syk consensus sequence mainly consisted of  
acidic amino acids. Syk and Lyn independent site motif contains acidic amino acids as 
well as many other amino acids without really projecting a specific kinase substrate 
motif.  
 
3.3.4 Known Syk and Lyn Substrates and Sites 
As expected some of the known substrates of Syk and Lyn can be observed 





previously reported sites. Y759 of PLCg-2, Y330 of PRKCAB and Y330 of BTK has 
been shown as Syk substrates in previous reports. In addition, HCLS1 shows a 
homologus site for Human HCLS1 Y3340 site. Further, BLNK and Cbl shows two pY 
sites though they are different from the homologous reported sites for human. There are 
several Lyn substrates that have also been identified among the Lyn dependent pY sites. 
Y340 of BTK, Lyn auto-phosphorylation site of Lyn, Y21 of PTPN6. Also two sites on 
PAG1 and DOK2 has also been reported which are previously reported Lyn substrates 
but the sites we identify are slightly different from what is previously reported.  
 
3.3.5 Kinases and Phosphatases 
Among the proteins that were modulated as mentioned above there were a 
significant number of kinases and phosphatases. The peptides corresponding to those are 
shown in figure 4a, b and supplementary figure 2. There were 12 tyrosine kinases, 31 
serine/threonine kinases, and 3 dual specificity kinases among the molecules identified 
with tyrosine phosphorylation. Further there were 13 tyrosine phosphatases and 2 
serine/threonine phosphatases.  
 
3.3.6 Tyrosine Kinases in B-cells 
The ordered activation of three different non-receptor tyrosine kinases; Lyn, Syk 
and Burton Tyrosine Kinase (BTK) is required for proper BCR signal transduction.  The 
activation and recruitment of Lyn and Syk to the BCR complex influence the activity of 
BTK through PI-3K and PI(3,4,5)P3 production. Inhibition of PI-3K or BTK impair 





propagation. Cross-linking BCR induces phosphorylation on Y223 and Y551 on BTK, 
Syk and Lyn dependent regulation of these sites has been previously reported28-30. Human 
Y551 (Chicken Y549) is an activation site for BTK during BCR signaling. The mutation 
of Y551 abrogated calcium immobilization in B-cells and it has been suggested that 
transphosphorylation of BTK Y551 is essential for BCR signaling and it is mediated 
through the concerted action of Lyn and Syk29, 30. Further Syk dependent regulation of 
BTK is known to mediate through BLNK28. We have correctly identified this site as a 
Syk or Lyn dependent phosphosite in this study. Phosphorylation on Y551 activates BTK 
and induces autophosphorylation at Y223 (Chicken Y220) which is known to be 
controlled by Lyn and Syk and it has been correctly classified under Syk and Lyn 
dependent sites in this study. Among the other identified BTK sites Y40 and Y334 are 
Lyn dependent and Syk dependent respectively.  For both these sites upstream 
kinase/phophotase prediction yielded as a potential Src site or TC-PTP site. However the 
amino acid composition around the tyrosine residue deviates from typical Lyn or Syk 
consensus sequence. Y225 (Chicken Y222) has been identified as a Syk and Lyn 
dependent site, although any upstream kinase has not been reported to this site as well as 
upstream kinase/phosphatase prediction does not report a potential kinase or phosphatase. 
The other two identified sites, Y86 and Y318 are unique to chicken BTK and these sites 
are Lyn dependent and Syk or Lyn dependent respectively.  The analysis of BTK 
phosphorylation revealed Syk and Lyn dependent nature of Y551 and Y223 as reported 
previously and our study further indicates that Y40, Y86, Y225, Y334 on BTK may also 





Since the data provides evidence for Syk and Lyn dependent BTK regulation 
under the experimental conditions, to further confirm, we searched for known BTK 
substrate phosphorylation sites. BTK phosphorylates four tyrosine residues on PLCg2 
during BCR signaling31. Out of those Y753 (Chicken Y754), Y759 and Y1217 have been 
identified in this study. Y759 is Syk dependent whereasY753 and Y1217 are Syk and 
Lyn dependent. BTK controls sustained calcium signaling in B-cells via site specific 
phosphorylation at Y753 and Y759 which are located at SH2-SH3 linker region32. 
Glycoprotein VI also stimulates Y753 and Y759 phosphorylation through BTK33. Further 
BTK mediates chemokine controlled migration of B-cells via PLCg2 Y759 
phosphorylation34.  Y248 (Chicken Y246) of GTF2I is another BTK substrate site that we 
have identified. Phosphorylation of Y248 of GTF2I is thought contribute to 
transcriptional activation linking BCR receptor engagement to modulation of gene 
expression35.  
Lyn was thought to be the only Src family kinase present in DT40 cells and a 
recent study reported detection of Fyn mRNA in Lyn deficient DT40 cells at about 10 - 
20% level compared to Lyn in wild type DT40 cells36. It has also been postulated Fyn 
may contribute to positively regulate BCR signaling under these conditions. Interestingly 
in this study we have identified activation sites Y420 and Y28 on Fyn both showing Lyn 
dependent phosphorylation. Further Lyn dependent phosphorylation of autocatalytic sites 
of FER (Y714), EphA2 (Y772), and a motif very similar sequence in EphA2 







3.3.7 Serine/Threonine Kinases in B-cells 
There are several serine threonine kinases that are reported to be directly 
phosphorylated by Syk or Lyn; MAP4K1 and PKACA are Syk substrates whereas 
PKACD is a Lyn substrate. In addition there are many cellular pathways that are 
modulated by Syk and Lyn including BCR signaling through serine/threonine kinases. 
One of the main groups of serine/threonine kinases identified in this study is MAP 
kinases mainly show Syk and Lyn independent phosphorylation in the activation loop 
tyrosine residue and in certain cases the phosphorylation on the nearby threonine residue 
has also been identified. Upon BCR engagement tyrosine kinases activates Ras-GTP 
complex which in turn activates the MAP kinase kinase c-Raf initiating MAP kinase 
cascade leading to activation of transcription factors. The serine/threonine kinase c-Raf 
activates dual specificity MAP kinase kinases (Mek1 and 2).  Mek1 and Mek2 
phosphorylates activation loop threonine and tyrosine residues simultaneously and 
activates transcription factors; Extracellular-regulated kinase-1 and 2(ERK1 and 2). In 
addition Ras-MEKK1 pathway activates JNK1/2 and p38 via Mek4/7 and Mek 3/5/6 
respectively. In this study we have identified ERK2, p38, JNK 2 and 3 with Syk and Lyn 
independent phosphorylation and it can be postulated that this change is mediated 
through a common upstream protein such as Ras. It has been reported that during IL5 
signaling in eosinophil, MAP signaling cascade is activated by Jak2 and Lyn through 
tyrosine phosphorylation on Ras37. Therefore we believe that the observed 
phosphorylation changes in the aforementioned proteins may be modulated through a 





Cyclin dependent kinases (CDKs) are considered to be the closest relatives of 
MAPKs and there are numerous CDKs identified in this study which are also seem to be 
independent of both Syk and Lyn. Colocalization and coimmunoprecipitation studies 
have provided evidence for direct association between CDK2 and Lyn in ara-C treated 
cells38. Further it has been reported that Lyn phosphorylates Tyr15 of CDK2 leading to 
inhibition of CDK2 activity. These findings suggest that the association of Lyn and 
CDK2 in ara-C-treated cells may contribute to regulation of CDK2-dependent cell cycle 
checkpoints. In addition it is known that CDK is inhibited in Syk dependent tumor 
suppression mechanism39. In this study CDKs show phosphorylation at the activation site 
in a Syk and Lyn independent manner. Therefore it can be postulated that inhibitory 
phosphorylation on CDKs are directly or indirectly regulated by Syk and Lyn whereas 
activation is independent.   
 
3.3.8 Tyrosine Phosphatases in B-cells 
Lyn deficient B-cells are hyper responsive to receptor stimulation, also these cells 
showed elevated MAPK activation, enhanced calcium flux and hyper activation of AKT 
suggesting a negative role for Lyn in BCR signaling12. The negative regulatory effects of 
Lyn are mediated through phosphorylation on two main inhibitory receptors; FcgRIIb1 
and CD2212. Lyn phosphorylates FcgRIIb1 at Y292 which in turn recruits SHIP-1 leading 
to a cascade of negative regulatory events. CD22, Lyn and SHP-1 form a regulatory loop 
in B-cells where Lyn phosphorylates ITIM domain of CD22 leading to SHP-1 
recruitment mediating suppressive effects of CD22 on MAPK activation and Calcium 





SHIP-1 and SHP1. SHP-1 Y536 is known to be phosphorylated by Lyn. Along with 
Y536 we have identified Lyn dependent phosphorylation on SHP-1 Y64, Y 301, and 
Y564 also. Phosphorylation on Y536 and 564 by Src kinase have been reported to 
activate SHP-1 and we believe that all the above site are in Lyn phosphorylation motifs 
and potential Lyn sites which might be happening as a part of the regulatory mechanism. 
In addition we have identified Y856 on SHIP-1 with Lyn dependent phosphorylation and 
Y1022 shows a Syk and Lyn dependent phosphorylation. Studies show that the SH2-
domain of SHIP1 can bind to the C-terminus of the SHIP1 molecule via Y1022 
phosphorylation and this interaction regulates the association between different forms of 
SHIP1 and Ig-α40. Also it has been suggested that proteins such as DOK1 and SHC 
interact with Y1022 phosphorylated SHIP-1 during SHIP-1 dependent cell migration41.  It 
has been identified that Y1020 is one of the main contact sites for the SHC-
phosphotyrosine binding domain and Lck phosphorylates these sites in T-cells42.  
Another important group of tyrosine phosphates that have been identified is 
receptor tyrosine phosphatases. CD45/PTPRC has been shown to be an essential 
regulator of T- and B-cell antigen receptor signaling1, 14. It functions through either direct 
interaction with components of the antigen receptor complexes or by activating various 
Src family kinases required for the antigen receptor signaling. Regulation of Lyn activity 
by dephosphorylating negative and positive activation sites of Lyn by CD45 has been 
reported43 but Lyn phosphorylation of CD45 has not been reported. Y880 of CD45 show 
Lyn dependent phosphorylation change however this site has not been reported before. 
Y1015 shows a Syk dependent phosphorylation change however based on the motif it is 





negative regulator of cytokine receptor signaling44. Further Y705, Y978 and Y1073 show 
Syk and Lyn dependent phosphorylation changes. In B-cells CD45 activity is 
compensated by CD148/PTPRJ14, 45 and we have identified Y1045 as a Lyn dependent 
site. Similar to CD45-deficient mice, B cells from CD148-deficient mice show partially 
blocked B cell development and activation as well as greater phosphorylation of the 
inhibitory C terminus of Lyn14, 45.  
 
3.3.9 Adapter Proteins in B-cells 
Once Lyn, Syk and BTK are activated, progression of signaling requires tyrosine 
phosphorylation dependent activation of a number of adaptor molecules46, 47. We have 
identified numerous B-cell adaptor proteins as shown in figure 3c, with phosphorylation 
site changes in Syk and Lyn dependent manner. Interestingly there are several 
phosphorylation sites of common proteins such as VAV2, PAG1 changing independent 
of Syk and Lyn.  PLCg2 is an adaptor protein in the BCR signalosome, the recruitment 
and activation of PLCg2 and elevation of Ca2+ ion concentration are important secondary 
steps in BCR signaling. We have identified several BTK substrate sites on PLCg2 in this 
study and discussed above. PAG1 is another important adaptor protein in B- and T-cells 
which negatively regulates the receptor signaling. PAG1 is phosphorylated in resting T-
cells by Fyn and the phosphorylation decreases in response to TCR signaling46, 47. Y163 
and Y181 show increased phosphorylation with loss of either kinase and this is 
interesting because PAG1 is phosphorylated in the absence of the receptor signal48. These 
sites are necessary for suppressing c-Src activity by acting as scaffolds for c-Src binding 





PI3K(PIK3AP1 or BCAP) is another B-cell adaptor protein that we have identified with 
multiple phosphorylation sites.  Among those both Y594 and Y694 have been identified 
to be Syk and Lyn dependent and the above C-terminal tyrosine sites are known to be 
phosphorylated by Abl49. CBL is an E3 ligase that negatively regulates many signaling 
pathways that are triggered by cell surface receptor activation. Syk is negatively 
regulated by CBL by ubiquitination and degradation upon phosphorylation on Y323 by 
Lyn50. We have identified Y371 and Y674 as Syk and Lyn dependent phosphorylation 
sites. EGFR and insulin receptor have been suggested as regulators for Y371 
phosphorylation leading to block the ubiquitin ligase activity of CBL51. On the other hand 
Y674 has been suggested to be regulated by Syk52. Syk and Lyn are upstream kinases in 
many cellular pathways and functional networks in B-cells. It is well accepted that the 
signaling cascades starting from cell surface receptors and propagates via Syk and Lyn to 
modulate various cellular pathways via kinases, phosphatases and various adaptor 
proteins.  
 
3.3.10 Pathway Analysis 
The protein lists were extracted from the five categories of phosphotyrosine sites 
(Syk dependent, Lyn dependent etc.) and the pathways that are modulated in each 
category was investigated.  As expected BCR signaling as well as other prominent B-
cells pathways such as PI3K signaling and FcRIIB were identified in all lists. Previously 
we showed Syk dependent ubiquitination in DG75 cells and we have again identified 





Syk dependent mTOR signaling and Lyn dependent Leukocyte extravasation as 
prominent pathways which are described below.  
 
3.3.11 Syk-dependent mTOR Signaling 
In B-cells mTOR positively regulates protein synthesis by activating two major 
signaling pathways, p70S6K/RPS6 and 4E-BP1/eIF4E and turn controls cap-dependent 
translation of mRNAs with 5’ untranslated regions which is a characteristic of transcripts 
of oncogenic proteins53. mTOR is constitively active in acute myeloid leukemia (AML) 
cells and important in AML cell survival. Inhibition of mTOR in AML cells has been 
associated with both anti-proliferating and pro-differentiation effects54. In B-cell 
lymphoma Syk is a critical regulator of mTOR activity55, 56. Syk inhibition reduces 
viability and promotes differentiation in AML cells.  However the downstream signaling 
effectors of Syk are not known yet in this process. AKT is an upstream kinase for mTOR, 
and in our study we have identified AKT family protein, AKT2. AKT2 shows Syk 
dependent phosphorylation on Y240 in THFPQFSySASIRE sequence which is highly 
conserved across species. However the upstream kinase for this site has not been 
reported. In addition we have identified perturbation in regulation of eIF4 and p70S6K 
signaling pathways which are directly downstream of mTOR, again in a Syk dependent 
manner, further supporting Syk dependent regulation of mTOR. Figure 6 illustrates the 
connectivity between mTOR, and regulatory pathways of eIF4 and p70SK through the 







3.3.12 Lyn-dependent Leukocyte Extravasation 
Leukocyte extravasation is a primary component in cellular immune response in 
which leukocytes migrate from blood to tissue. This process is associated with cell to cell 
communication, hematological system development and immune cell trafficking. Lyn as 
well as other Src family kinases are known to be involved in leukocyte extravasation 
though this function of Lyn has not been extensively investigated .A recent report 
identifies Lyn as a redox sensor that mediates initial neutrophil recruitment to 
inflammatory sites. Lyn activation is dependent on wound-derived H2O2 after tissue 
injury. Inhibition of Lyn has reduced the recruitment of neutrophils to inflammatory site. 
For the enhanced permeability and leukocyte extravasation, tyrosine phosphorylation of 
catenin and VE-cadherin are necessary. Further it has been reported that phosphorylation 
of different tyrosine of VE-cadherin is regulated in an opposing manner where not only 
phosphorylation but also dephosphorylation by phosphatases such as SHP-2 plays a role 
in regulating leukocyte extravasation. In our study we have identified several prominent 
proteins in leukocyte extravasation such as catenin, focal adhesion kinase, and PTPN11 
(SHP-2). SHP-2 shows Lyn dependent phosphorylation sites with a potential Lyn 
substrate motif SARVyENVG. The network of proteins in Lyn dependent Leukocyte 
extravasation is illustrated in figure 7.  






Previous studies have reported regulation of BCR signaling and other cellular 
pathways by Syk and Lyn in compensatory as well as opposing manner. However 
investigation of individual phosphorylation events and pathways provided only limited 
information on downstream effects of these two upstream kinases. Therefore we 
performed a proteomics level investigation on Syk and Lyn dependent pathways in B-
cells using multiple DT40 cell lines; wild type, Syk deficient, Lyn deficient, and Syk and 
Lyn double deficient. To further enhance phosphotyrosine identificatio , we sequentially 
enriched peptide samples with phosphotyrosine antibody beads and PolyMAC-Ti. This 
approach enabled us to identify and quantify 1218 tyrosine phosphorylated peptides 
across four cell lines. We grouped these phosphotyrosine peptides into five categories as 
Syk dependent, Lyn dependent, Syk and Lyn dependent, Syk or Lyn dependent and 
Independent based on the phosphorylation changes across cell lines. The examination of 
phosphotyrosine sites on kinases, phosphatases and adaptor proteins suggested potential 
regulatory events mediated by Syk, Lyn or other kinases in B-cells. Furthermore, 
canonical pathway analysis revealed Syk dependent mTOR pathway and Lyn dependent 
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Figure 3.1: Basic Evaluation of Sequential Enrichment.  Basic Evaluation of Antibody-
based Enrichment and Antibody-PolyMAC Sequential Enrichment for Tyrosine 
Phosphorylated Peptides. (a) Antibody-based enrichment, (b) antibody-PolyMAC-Ti 
based sequential enrichment indicating the numbers of total peptide (blue), 
phosphopeptides (red) and tyrosine phosphorylated peptides (green)(c) comparison of 
tyrosine phosphorylated peptide enrichment between antibody and antibody-PolyMAC-










































































Figure 3.2: Experimental Work-flow. DT40 wild type, DT40 Syk-/-, DT40 Lyn-/- 
and DT40 Syk-/-Lyn-/- double knockout cell lines were cultured. Proteins were 
extracted and digested. The peptide sample was first enriched with anti 
phosphotyrosine antibody beads, then by PolyMAC-Ti. A standard peptide library 








Figure 3.3: Phosphotyrosine Site Classification and Motif Analysis. (a)Based on 
quantitative changes on each phosphotyrosine residue, the sites are classified into five 
categories as, (i) Syk dependent, (ii) Lyn dependent, (iii) Syk and Lyn dependent, (iv) 
Syk or Lyn dependent and (v) Syk and Lyn independent. The graph demonstrates the 
numbers of phosphotyrosine sites (blue) and proteins (red) under each category. (b)- (f) 
Motif logos for the above five categories of phosphotyrosine sites 
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PROTEIN FRACTIONATION USING IMAC-Cu 
 
4.1 Introduction 
The proteomes of mammalian cells, tissues, and body fluids are complex and 
display a wide dynamic range of protein concentrations. The number of protein 
sequences in humans is estimated to be approximately 100,000, and possibly the number 
may increase by 10-100 times with different isoforms1. In addition the dynamic range of 
protein concentrations2 can span over seven orders of magnitude in cells and ten orders of 
magnitudes in plasma3. Consequently, analysis of the proteome is a much more 
challenging task than that of the human genome and the challenge is to provide sufficient 
amount of information in experimental datasets to match the underlying complexity. 
Mass spectrometry has evolved as the state of the art technology for proteomics analysis 
due to its speed, sensitivity, accuracy and ability to couple with chromatographic 
techniques4. In spite of new technologies, analysis of complex biological mixtures, ability 
to quantify separated protein species, sufficient sensitivity for proteins of low abundance, 
quantification over a wide dynamic range, ability to analyze protein complexes, and high 
throughput applications is not yet fulfilled. In addition, there is an added layer of 
complexity to biological samples due to the high background and matrix components 





The proteins secreted by particular types of cells, the so-called secretomes, play 
important roles in regulation of many physiological processes via paracraine or autocrine 
mechanisms, and they are of increasing interest as potential biomarkers and therapeutic 
targets in disease5, 6. Investigation of secreted proteins is quite challenging due to 
technical difficulties associated with analysis such as (i) low protein concentrations due 
to their high dilution in body fluids or cell culture media, (ii) masking and contamination 
of the secretome by cytoplasmic or other normally non-secreted proteins released 
following cell lysis and death, and (iii) masking by serum proteins (i.e. fetal bovine 
serum) normally present in the culture media7, 8.  
Proteomics profiling is a relevant approach to biomarker discovery extensively 
utilized in secretome analysis. Advances in techniques based on liquid chromatography 
and two dimensional polyacrylamide gel electrophoresis in combination with mass 
spectrometry have significantly facilitated the challenging detection of secreted proteins9 
However, there is no stand-alone technique that can satisfactorily reduce the complexity 
of protein samples. Therefore many new approaches have been developed to address the 
challenges present in proteome analysis. In this context protein fractionation methods 
have become pivotal in reducing sample complexity. 2D gel electrophoresis and 
chromatography are widely used to fractionate protein samples. Since it was first 
introduced10, 2D gel electrophoresis has evolved and become a powerful technique for 
protein separation as well as the method of choice for differential protein expression 
analysis. In 2D gel electrophoresis proteins are separated based on isoelectric point and 
molecular weight in the two dimensions. This technique has an excellent resolving 





proteins, inclusing multiple spots that contain different molecular forms of the same 
protein11. Nevertheless, it suffers from several major limitations related to 
reproducibility12, poor representation of low abundant proteins13 and, proteins at the 
extremes of acidity, basicity size and hydrophobicity14, and difficulties in automation of 
gel-based techniques15. Moreover, the comigration of multiple proteins in a single spot 
makes quantification difficult. 
Due to limitations in 2D-gel electrophoresis, recent developmental efforts have 
been mainly focused on chromatographic techniques. A wide range of physical and 
chemical properties of proteins can be used fractionate complex protein samples such as 
cell lysates and serum. Physical properties such as molecular weight, shape and charge as 
well as chemical properties such as isoelectric point (pI), hydrophobicity, and affinity to 
various ligands are commonly used in separation techniques at present16. There is a wide 
variety of chromatographic methods using different properties of proteins to fractionate 
proteins16-18. For example reverse phase (RPC) and hydrophobic interaction (HIC) 
chromatography use hydrophorbic interactions between proteins and the stationary phase, 
ion exchange chromatography is based on the charge of proteins, size exclusion 
chromatography uses the differences in the size of proteins and affinity chromatography 
utilize the interaction between proteins and various affinity ligands mounted on the 
stationary phase. Each separation method demonstrates strengths and weaknesses. RPC 
and HIC provide higher resolving power to smaller proteins (> 30000 Da) and peptides 
than larger proteins. However, their mobile phases may cause protein denaturation 
leading to precipitation or stronger adsorption and making it more difficult to elute the 





allowing the proteins retain their native conformations. In addition, ion exchange resins 
are very robust and can be used for hundreds of separations. The main disadvantages of 
ICX resins are their poor selectivity and tendency to adsorb to either positively or 
negatively charged proteins at the initial pH condition. In size exclusion chromatography 
(SEC) the sample does not interact with the stationary phase, instead, the stationary phase 
acts as a molecular sieve. However SEC provides the lowest resolution and lowest 
capacity while also causing the highest dilution of samples.  
The basic principle of affinity chromatography is based on the ability of proteins 
to bind selectively and reversibly to a complementary molecule attached to a solid 
support16, 19. Thus, proteins that do not possess complementary binding sites for the 
affinity ligands pass directly through the column or can be eluted easily in early fractions. 
The bound proteins are then eluted in the reverse order of the strength of the interaction. 
Although antibodies directed against specific proteins or a group of proteins remain the 
most popular affinity method, there are numerous other methods that have been 
developed over the years. These methods include, lectin affinity for glycoproteins20-23 
and, immobilized metal affinity chromatography (IMAC) containing nickel for histidine 
tagged proteins24 or gallium for phosphoproteins25.  
Immobilized metal affinity chromatography was first introduced in 1975 with the 
initial aim of isolating nucleotides. Later, IMAC was used to immobilize proteins 
including enzymes, antibodies, and recombinant proteins. Currently, IMAC-Ni is 
extensively used to purify histidine tagged proteins, and IMAC-Fe is commonly used to 
enrich phosphopeptides. In several instances IMAC functionalized with metals such as 





classify proteins based on metal binding and non-binding properties. Furthermore, IMAC 
has been used to isolate specific groups of metal binding proteins such as 
metallothionine, prion proteins, matrilysin, and non-heme iron containing 
metalloproteins. While studying metal-protein interaction with different metals 
immobilized on IMAC, we observed that Cu2+ demonstrated a unique ability to capture 
over 98% of the protein component of cell lysate and serum samples. Furthermore, it was 
capable of successfully isolating secreted proteins over FASP from the complex matrix. 
This suggested that copper – protein interaction can be applied to capture proteins from 
complex mixtures and matrices and subsequently fractionate to identify low abundant 
proteins. In chapter 4, we describe the development of IMAC-Cu based protein 














4.2.1 Preparation of Protein Samples 
The concentrations of all protein samples were measured using BCA assay before 
mixing with IMAC-Cu beads for capturing experiments. Standard protein mixtures: 1 
mg/ml solutions of bovine serum albumin, β-lactaglobulin, catalase, β-casein and 
ovalbumin were prepared separately and equal amounts were mixed to obtain standard 
protein mixtures. Human and Swine serum samples: Serum sample aliquots were stored 
in -80oC and thawed on ice before use. Serum samples were diluted twenty times with the 
loading buffer before mixing with the IMAC-Cu beads. HEK 293 cell lysates: HEK 293 
cells were grown in DMEM (high glucose) media supplemented with 10% FBS and 1% 
penicillin/streptavidin. The cells were collected at 80% confluence, washed with PBS and 
pelleted. The cell pellets were stored in -80oC until use. Binding buffer was added to the 
cell pellet and lysed with homogenizer using short pulses. The sample was centrifuged 
and the supernatant was collected for further experiments.  
 
4.2.2 Preparation of Secreted Protein Samples 
AGS cells were plated on sterile petridishes and cultured in DMEM containing 
heat inactivated FCS (10%) at 37 oC and 5% CO2 to 80% confluence. Then the cells were 
washed with serum and phenolred free DMEM media. The cells were infected with 
Helicobacter piroli strain 26695 at M.O.I 100 in serum and phenolred free media (pH 





remove detached cells and bacteria. The samples were centrifuged at 4oC for 20 minutes 
at 15000 rpm.  
 
4.2.3 Preparation of IMAC-Cu Beads 
Charging IMAC beads with the metal was carried out according to the instruction 
given in the product manual. Briefly, 250 ul of the slurry was pipetted into a spin column. 
The storage solution was removed by centrifugation using a bench top centrifuge for 1 
minute. Then the beads were resuspended in distilled water by vortexing for 10 seconds 
and centrifuged to remove water. This step was repeated three times. Next the beads were 
washed with equilibration buffer (50 mM sodium acetate, 300 mM NaCl, pH 4) twice. 50 
mM Copper (II) sulfate solution was added to beads and mixed for 10 minutes. Again the 
beads were washed with equilibration buffer twice and distilled water thrice. Finally the 
beads were washed with the binding buffer once.  
 
4.2.4 Protein Capture by IMAC-Cu  
Protein sample (maximum amount 1 mg) was dissolved in binding buffer (250 l) 
and loaded onto the IMAC-Cu beads in the spin column. The sample was briefly votexed 
and put in the shaker for 10 minutes at room temperature. The flow-through was 
collected into a 1.5 ml tube.  
 
4.2.5 SDS-PAGE Gel 
2% volume of the above flow-through was taken and 2.5 l of LDS buffer and 1 l 





nano-pure water. The protein mixtures were boiled at 95oC for 5 min and loaded onto 
12% Bis-tris SDS-PAGE gel and the chamber was filled with 1X MOPS buffer. Then 
proteins were separated on the ges at 170V for 1 hour.   
 
4.2.6 Gel Staining 
The gel was removed from the gel cassette and washed in nano-pure water for 30 
minutes. Then it was washed with fixing solution (50% ethanol and 10% glacial acitic 
acid) for 10 minutes. Next the gel was washed in rinsing solution (50% ethanol) for 5 
minutes and nano-pure water for another 5 minutes. The gel was washed with 0.02% 
sodium thiosulphate solution for 2 minutes and another 5 minutes. Next the gel was 
stained in 0.1% silver nitrate solution of 20 minutes. After several short water washes, the 
gel was developed using the developing solution (2% sodium carbonate, 0.04% 
formaldehyde, 0.08% sodium thiosulfate). Finally gel was washed with 1% acetic acid 
solution and nano-pure water.   
 
4.2.7 Off-line Protein Fractionation 
Off-line fractionation was carried out on a Agillent-1100 HPLC system using 
ProPac IMAC-10 column (Thermo) functionalized with Cu2+ following the instructions 
given in the product manual. Buffer A: 20 mM HEPES, 0.3 M NaCl, pH 7 and buffer B: 












0.0 0.0 1.00 200 
5.0 0.0 1.00 200 
5.5 10.0 1.00 200 
10.0 10.0 1.00 200 
10.5 15.0 1.00 200 
15.0 15.0 1.00 200 
15.5 17.5 1.00 200 
20.0 17.5 1.00 200 
20.5 20.0 1.00 200 
25.0 20.0 1.00 200 
25.5 25.0 1.00 200 
30.0 25.0 1.00 200 
30.5 30.0 1.00 200 
35.0 30.0 1.00 200 
35.5 40.0 1.00 200 
40.0 40.0 1.00 200 
40.5 50.0 1.00 200 
45.0 50.0 1.00 200 
45.5 75.0 1.00 200 
50.0 75.0 1.00 200 
50.5 100.0 1.00 200 
55.0 100.0 1.00 200 
 
 
4.2.8 LC-MS/MS Analysis 
Peptide samples were redissolved in 10 µl of 0.25% formic acid and injected into 
an Eksigent nano LC Ultra 2D system. The reverse phase C18 was performed using an 
in-house C18 capillary column packed with 5 µm C18 Magic bead resin (Michrom; 75 
µm i.d. and 30 cm of bed length). The mobile phase buffer consisted of 0.1% formic acid 
in ultra-pure water with the elution buffer of 0.1% formic acid in 100% CH3CN run over 





of 300 nl/min. The electrospray ionization emitter tip was generated on the packed 
column with a laser puller (Model P-2000, Sutter Instrument Co.). The Eksigent Ultra 2D 
HPLC system was coupled with a hybrid linear ion trap orbitrap mass spectrometer 
(LTQ-Orbitrap Velos; Thermo Fisher). The mass spectrometer was operated in the data 
dependent mode in which a full scan MS (from m/z 300 – 1700 with the resolution of 30, 
000 at m/z 400) was followed by 20 MS/MS of the most abundant ions. Ions with charge 
state +1 were excluded.  The mass exclusion time was 90 s.  
 
4.2.9 Database Search 
The LTQ-Orbitrap raw files were searched directly against human database using 
SEQUEST HT Proteome Discoverer (Version 1.4, Thermo Fisher). Proteome Discoverer 
created DTA files from raw data files with minimum ion threshold 15 and absolute 
intensity threshold 50. Peptide precursor mass tolerance was set to 10 ppm, and MS/MS 
tolerance was set to 0.8 Da. Search criteria included a static modification of cysteine 
residues of +57.0214 Da and a variable modification of +15.9949 Da to include potential 
oxidation of methionine Searches were performed with full tryptic digestion and allowed 
a maximum of two missed cleavages on the peptides analyzed from the sequence 
database. False discovery rates (FDR) were set to 1% for each analysis. Proteome 
discoverer generates a reverse “decoy” database from the same protein database and any 
peptide passing the initial filtering parameters that were derived from the decoy database 
and define as false positive identification. The minimum cross correlation factor (Xcorr) 





predominant target FDR of 1% based on the number of random false-positive matches 
from the reveres “ decoy” database. Thus, each dataset had its own passing parameters.  
 
4.2.10 Bioinformatics 
The list of proteins obtained upon analysis of secreted protein samples was 
subjected to gene ontology component analysis using Gene Ontology enRIchment 
anaLysis and visuaLizAtion tool (GOrilla)26, 27 and interaction networks were generated 








4.3 Results and Discussion 
 
4.3.1 Protein Capture by IMAC-Cu 
Affinity chromatography was first introduced for enzyme purification and then it 
was extended to receptor proteins, immunoglobulins, glycoconjugates, nucleotides and 
even to whole cells and cell fragments29. In affinity chromatography the interaction 
between protein and a specific affinity ligand on the stationary phase is used. The ligand 
and protein interacts reversibly through a combination of electrostatic, hyrdoporbic as 
well as short range Van der Waals forces and hydrogen bonding29. On the other hand 
immobilized metal affinity chromatography (IMAC) relies on formation of weak 
coordinate bonds between immobilized metal and the protein30. The interaction used in 
IMAC depends on the formation of coordinated complexes between the metal ions and 
the electron donor groups on the protein surface. Histidine shows the strongest interaction 
with immobilized transition metals in which the electron donor groups on the imidazole 
ring of histidine forms the strong coordination complexes with transition metals and the 
actual protein retention on IMAC is directly correlated to the availability of histidine 
residues31.  In addition cystidine contributes to the metal protein interaction through thiol 
groups and aromatic side chains of trypsin, phenylalanine, and tyrosine can also interact 
with metal ions. Since all proteins contain these amino acid residues, it is expected that 
all proteins are capable of binding to IMAC columns providing an affinity 
chromatographic method that can be used to retain a significant fraction of the proteome 





Therefore, first we investigated the protein retention capability of different metals 
using IMAC beads. IMAC beads containing iminodiacetic acid (IDA) as the metal 
chelator, were functionalized with several metal ions that are commonly found in 
biological systems, transition metals: Copper(II), Zinc(II), Manganese(II), Iron(III), 
Cobalt(II), Nickel(II), and Titanium(IV) and non-transition metals Calcium(II) and 
Magnesium(II). Then equal amounts of protein samples were loaded on to the beads, 
incubated and the flow through was analyzed.  Figure 1 shows the gel images of the flow 
through analysis for both cell lysate and serum samples and they demonstrate that Cu(II) 
processes a unique ability to capture majority of proteins while the other metals show 
varying degree of capturing ability. According to previous studies, high molecular weight 
region of a serum gel is mainly consisted of -glubulins and they interact with metal ions 
in the order of Cu2+> Ni2+>Zn2+>Co2+. This same pattern persists in the gel image of the 
serum sample further supporting our experimental data. In addition it has been reported 
that Zn2+ requires two vicinal histidine residues on the protein surface for binding, Ni2+ 
requires at least two histidine residues and Cu2+ requires only one histidine residue on the 
protein surface further supporting our observation of unique protein capture by IMAC-
Cu. 
 
4.3.2 Evaluation of Protein Capture Efficiency of IMAC-Cu 
Based on BCA assay, we observed over 98% protein capture by IMAC-Cu for 
both cell lysate and serum samples. In order to further evaluate the protein capture 
efficiency of IMAC-Cu, we used human serum samples due to two reasons; (i) the 





availability of serum protein depletion kits for highly abundant proteins encompassing 
>99% of the serum which would enable comparison of protein capture by IMAC. 
Therefore we incubated human serum samples with IMAC functionalized with the 
aforementioned metals as well as high abundant protein depletion antibody beads as a 
positive control and IMAC without any immobilized metal as a negative control. The 
flow-through from each of the above experiments was collected, digested and analyzed in 
the mass spectrometer with a spiked in peptide library for quantification. Each protein 
was quantified related to human serum sample. Figure 2 indicates the percentage of 
remaining protein amount in the flow-through after capture by IMAC-Cu, Ni, Zn and Co. 
It is clearly visible that the protein captures by IMAC-Cu is comparable with the antibody 
beads and the other metals show protein capture in the order of Ni2+>Zn2+>Co2+ as 
inferred based on previous reports. The above results further support that IMAC-Cu 
shows the best capture for proteins providing the highest protein adsorption do develop a 
more general protein fractionation method.  
 
4.3.3 Protein Fractionation on IMAC-Cu 
Three possible mechanisms for immobilized metal ion chromatography have been 
proposed; ion exchange, ligand exchange and hydrophobic interaction. The primary 
binding mode for proteins on to IMAC is considered to be ligand exchange. It has been 
reported that nitrogen containing ligands such as ammonia and tris salts reduce the 
affinity to metal chelate column for proteins indicating the sensitivity to amine groups.  
Therefore primary binding sites for of proteins are nitrogen containing ligand such as the 





amide nitrogen. This is further supported by the fact that basic proteins are strongly 
retained on the column and the proteins can be successfully eluted using nitrogen 
containing ligands such as imidazole and glycine. The increase in the affinity of the 
proteins for the metal chelate as the pH increases also suggests that uncharged amino 
groups are the species that interact with the metal ion.  In addition acidic proteins are 
weekly retained on the column and at acidic pH values the primary binding mode of 
proteins to IMAC is thought to be predominantly by ion exchange. However the 
hydrophobic interactions are not a significant mode of binding because even with high 
salt concentrations have not shown any significant effect on protein binding to IMAC 
columns.  
Therefore, to get a basic understanding of which elution system to be optimized 
we first investigated to fractionate proteins with linear pH gradient and imidazole 
gradient. Some of the representative chromatograms are shown in the figure 3. Based on 
that, pH elution from 7 to 4 did not elute all the proteins (Figure 3a). Although the 
separation was not clearly visible, imidazole gradient elution from with 50 mM imidazole 
could elute all the proteins in the sample (Figure 3b). In previous studies it has been 
shown that the strong protein retention ability of IMAC-Cu across a wide pH range from 
3.2 to 8.2 with a percentage retention to be about 93% at pH 8.1 and 88% at pH 7.2. The 
most commonly used approach to elute proteins from IMAC columns is adding imidazole 
to the elution buffer. Imidazole completes with the proteins that are bound through 
nitrogen ligands to the metal ion. Therefore we used 20 mM HEPES, 0.3 M NaCl, pH 7 
solution as buffer A and 20 mM HEPES, 0.3 M NaCl, 50 mM imidazole, pH 7 as buffer 





which are shown in Figure 4. Figure 4a shows 40 minute linear gradient above with 1 mg 
of cell lysate. The peak at 1.3 minutes probably represents proteins that do not bind to 
IMAC-Cu column or weakly binding proteins. Figure 4b shows-step wise elution with 
the above mentioned buffer B. With the step-wise gradient we were able to observe well 
separated groups of proteins compared to linear gradient.  
 
4.3.4 Evaluation of Ability to Identify Low Abundance Proteins 
The main goal of protein fractionation was to simplify the sample and identify 
low abundance proteins. Therefore after fractionation we analyzed some selected 
fractions using LC-MS/MS and compared with the cell lysate which is demonstrated in 
the figure 5. The spectral count values were obtained from a comprehensive list of cell 
lysate proteins published recently32 and we plotted them against the molecular weight of 
each identified protein in cell lysate and the fractions. It can be observed that there is a 
trend towards lower spectral counts in the fractions. This is more visible in the insert in 
which the percentage of identified proteins at different ranges of spectral counts has been 
illustrated. Further in the fractions, there are about 500 more proteins that are not in the 
published list we used and we believe they are very low abundance proteins that cannot 
be easily identified.  
Further we separated a human serum sample using the same step gradient as 
above and one peak was analyzed as shown in figure 6a. Again the list was searched 
against a recently published list33 of estimated concentrations of serum proteins. Analysis 
of serum in LC-MS/MS reports about 1 proteins and the fraction analysed reported about 





Figure 6c demonstrates the concentration profile for the proteins identified in the selected 
fraction compared to the proteins identified in the direct analysis of serum. It can be 
observed that the proteins identified in the fraction have relatively lower concentrations. 
Further out of the five hundred proteins that we identified in the fraction only about one 
hundred proteins can be found in the aforementioned list of serum proteins. Therefore we 
believe most of the proteins we have identified in the in the fraction are low abundance in 
the serum sample.  
 
4.3.5 Analysis of Secreted Proteins 
After identifying low abundance proteins from both cell lysate and serum samples 
using IMAC-Cu based fractionation, we applied the same method to separate a sample of 
secreted proteins collected after infection of AGS cells with Helicobacter pylori.  These 
samples have very low protein concentrations at microgram per milliliter level. In 
addition the various chemical components in the cell culture media and serum proteins 
make it difficult to capture and identify low abundance secreted proteins. Due to strong 
protein capture and separation capability of IMAC-Cu we were able to identify 
approximately one thousand proteins and about 20% of these were identified as 
extracellular proteins by the gene ontology component analysis26, 27 which is illustrated in 
figure 7. According to the above analysis, the sample is mainly enriched for proteins in 
extracellular region, extracellular organelle, membrane bound vesicles, and extracellular 
vesicle exosome which is indicated by the relatively higher p-value. The extracellular 
proteins identified were further analyzed using String 9 protein-protein interaction 





proteins such as cytokines and chemokines that are directly related to immune responses. 
Further it includes low abundance proteins such as interleukin 834 and 1835 which are 








We observed that IMAC-Cu can capture over 98% of proteins from both cell 
lysates and serum samples. Based on that, we developed a method to identify low 
abundance proteins in complex biological samples using an IMAC-Cu column on an 
HPLC system. Initially we investigated the protein fractionation capability of the column 
using both cell lysate and human serum. We obtained the best protein separation using a 
step-wise gradient and the bound proteins were eluted by changing the imidazole 
concentration in the elution buffer.  We applied this method to separate a sample of 
secreted proteins and nearly one thousand proteins were identified including low 
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Figure 4.2: Protein Capture Efficiency of IMAC-Cu. Protein capture efficiency of 
IMAC functionalized with different metals was evaluated using human serum samples 





















































Figure 4.3: Protein Elution from IMAC-Cu Column. (a) pH gradient from pH 7 to 4 
(b) imidazole gradient from 0 mM to 50 mM 
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Figure 4.5: Identification of Low Abundance Proteins from Cell Lysate. Log 
(spectral count) vs. Log (molecular weight) was plotted for the proteins identified. 
The insert shows the distribution of proteins across different ranges of spectral 
counts for the proteins identified in the fraction marked with a box in 4b 
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ABSTRACT: Engagement of the B cell receptor for antigen
(BCR) leads to immune responses through a cascade of
intracellular signaling events. Most studies to date have
focused on the BCR and protein tyrosine phosphorylation.
Because spleen tyrosine kinase, Syk, is an upstream kinase in
multiple BCR-regulated signaling pathways, it also affects
many downstream events that are modulated through the
phosphorylation of proteins on serine and threonine residues.
Here, we report a novel phosphopeptide enrichment strategy
and its application to a comprehensive quantitative phospho-
proteomics analysis of Syk-dependent downstream signaling
events in B cells, focusing on serine and threonine
phosphorylation. Using a combination of the Syk inhibitor piceatannol, SILAC quantification, peptide fractionation, and
complementary PolyMAC-Ti and PolyMAC-Zr enrichment techniques, we analyzed changes in BCR-stimulated protein
phosphorylation that were dependent on the activity of Syk. We identified and quantified over 13 000 unique phosphopeptides,
with a large percentage dependent on Syk activity in BCR-stimulated B cells. Our results not only confirmed many known
functions of Syk, but more importantly, suggested many novel roles, including in the ubiquitin proteasome pathway, that warrant
further exploration.
B cells are a vital component of the adaptive immunesystem that recognize foreign antigens through a cell
surface immunoglobulin known as the B cell receptor (BCR)
for antigen.1 B cell activation through BCR stimulation results
in proliferation and differentiation of B cells to form both
antibody-producing and memory cells. Cross-linking the BCR
by antigen engagement initiates phosphorylation of immunor-
eceptor tyrosine-based activation motifs (ITAMs) by the Src-
family kinase, Lyn, and subsequent recruitment of the tyrosine
kinase, Syk. Multiple adaptor proteins and effector proteins,
including the B cell linker protein BLNK, the guanine
nucleotide exchange factor Vav, phospholipase C-γ (PLCγ),
and phosphatidylinositide 3-kinase (PI3K), associate to form
signaling complexes2 that trigger downstream pathways such as
activation of Btk, mobilization of Ca2+,3 and activation of the
Ras/MEK/ERK pathway. The interaction between a phos-
phorylated ITAM and the SH2 domains of Syk, coupled with
the phosphorylation of the kinase on tyrosine, is essentially
required for all BCR-mediated signaling events.
The contribution of Syk to the adaptive immune response in
B cells is well-known and characterized. However, studies have
also identified a large number of diverse biological functions for
Syk, including cellular adhesion, phagocytosis, osteoclast
maturation, platelet activation, and vascular development.2
The involvement of Syk in the pathogenesis of allergy,
autoimmune diseases, carcinoma and hematological malignan-
cies has made it an important therapeutic target.2,4−6 Thus,
knowledge of the downstream pathways that mediate the
diverse functions of Syk are of considerable interest. Because
Syk is a tyrosine kinase, most studies have focused on Syk-
dependent tyrosine phosphorylation,7 which is largely limited
to immediate downstream signaling events and direct
substrates.8 Since Syk functions upstream of multiple pathways
of which serine/threonine kinases (e.g., PKC, Erk, Akt, etc.) are
major components, changes in its activity would be expected to
affect many downstream events regulated by protein
phosphorylation on serines and threonines. This study was
designed to identify Syk-dependent downstream pathways in
activated B cells at the proteomics level, focusing mainly on
such serine and threonine phosphorylation events.
Mass spectrometry is the major tool for analyzing protein
phosphorylation in a high-throughput manner. Phosphopeptide
enrichment is a necessary prerequisite in phosphoproteomics as
a result of the low stoichiometry of protein phosphorylation
Received: February 12, 2014
Accepted: June 6, 2014
Published: June 6, 2014
Article
pubs.acs.org/ac
© 2014 American Chemical Society 6363 dx.doi.org/10.1021/ac500599r | Anal. Chem. 2014, 86, 6363−6371
 Open Access on 06/06/2015
117
and the low abundance of phosphoproteins.9,10 Many different
approaches have been employed for phosphopeptide enrich-
ment11 and can be categorized mainly under affinity
purification,10,12−20 chemical derivatization,21,22 and chromato-
graphic separation.23−25 The most popular enrichment
approaches, immobilized metal ion affinity chromatography
(IMAC)13−16 and metal oxide affinity chromatography
(MOAC),17−20 chelate phosphopeptides to an affinity group
mounted on a solid support. This heterogeneous condition can
lead to poor binding accessibility and low reproducibility.
Recently, we introduced polymer-based metal ion affinity
capture (PolyMAC), a soluble reagent based on a titanium(IV)-
functionalized PAMAM dendrimer, which demonstrated
enhanced reproducibility and selectivity.26 Other studies have
shown the effectiveness of using both Zr- and Ti-based reagents
for phosphopeptide enrichment, as well as the ability of each to
capture a unique set of phosphopeptides.27 Therefore, to
complement our titanium-bound nanopolymer, we developed
PolyMAC-Zr, a zirconium(IV)-functionalized PAMAM G4
dendrimer. Here, we present PolyMAC-Zr as a novel reagent
for phosphopeptide enrichment and utilize the complementary
PolyMAC-Ti and PolyMAC-Zr enrichment methods to
examine the role of Syk-dependent phosphorylation in BCR
signaling. Quantitative phosphoproteomics based on stable
isotope labeling via amino acid in culture (SILAC)28 was
employed to identify downstream effectors of Syk. Using the
Syk substrate-site inhibitor piceatannol7 and comprehensive
sample fractionation with reversed-phase liquid chromatog-
raphy (RPLC) or hydrophilic interaction chromatography
(HILIC), we were able to quantify close to 5000 sites of
phosphorylation that were significantly affected by the activity
of Syk after BCR stimulation from over 16 000 identified
unique phosphorylation sites. Functional and pathway
annotations confirmed many known functions of Syk, but
also revealed potential novel roles, including a role in
modulating changes in protein ubiquitination.
■ METHODS
Synthesis of PolyMAC-Zr Reagent. Polyamidoamine
dendrimer generation 4 (PAMAM G4) solution (200 μL;
provided as 10% w/v in methanol; Sigma-Aldrich) was dried
and redissolved in 1 mL of dimethyl sulfoxide, then 6 mg of
Boc-aminooxyacetic acid, 15 mg of N-hydroxybenzotriazole
(HOBt), and 10 μL of N,N′-diisopropylcarbodiimide (DIC)
were added and reacted overnight. The mixture was transferred
to a 10 mL round-bottom flask, and an equal volume of 250
mM MES (2-(N-morpholino)ethanesulfonic acid; pH 5.5)
buffer was added to it. Next, 16 mg of carboxyethylphosphonic
acid, 16 mg of N-hydroxysuccinimide, and 160 mg EDC (1-
ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochlor-
ide) were added to the mixture and stirred overnight. The
solution was dialyzed against water, reacted with 0.1 M ZrOCl2
for 90 min, and evaporated to complete dryness. The solid was
redissolved in 80% trifluoroacetic acid and reacted for 90 min.
The mixture was dialyzed successively against a 1:4 DMSO/
water mixture and water. The final PolyMAC-Zr product was
stored at 4 °C.
Phosphopeptide Enrichment. Preparation of phospho-
peptide samples from DG-75 B cells and PolyMAC-Ti
enrichment were carried out in a similar fashion, as described
before.26 For PolyMAC-Zr, the peptide mixture was dissolved
in 100 μL of the loading buffer (200 mM glycolic acid, 1%
trifluoroacetic acid, and 50% acetonitrile); 5 nmol of PolyMAC-
Zr was added to it and incubated for 10 min. Then 250 μL of
capture buffer (300 mM HEPES buffer at pH 7.7) was added to
increase the pH above 6.3, and the mixture was transferred to a
spin column (Boca Scientific) containing 50 μL of Carbolink
coupling agarose gel (Thermo Scientific). The samples were
incubated for 10 min and centrifuged. The gel was washed with
loading buffer, washing buffer (100 mM acetic acid, 1%
trifluoroacetic acid, 80% acetonitrile), and water, then the
phosphopeptides were eluted with 400 mM ammonium
hydroxide.
Growing DG75 Cells in SILAC “Heavy” and “Light”
Media. For SILAC experiments, cells were grown to 50%
confluency in SILAC RPMI-1640 media (Gibco) substituted
with 10% dialyzed inactivated FBS (Sigma-Aldrich), 1% sodium
pyruvate, 0.5% streptomycin/penicillin, 0.05% 2-mercaptoetha-
nol, and either L-lysine and L-arginine for “light” samples or
13C6-L-arginine and
13C6-L-lysine (Isotec) for “heavy” samples in
5% CO2 at 37 °C.
Piceatannol Treatment and IgM Pathway Stimulation.
The cell cultures were plated at a density of 2 × 107 cells/mL
and treated with piceatannol at a concentration of 50 μg/mL.
Then the cells were incubated at 37 °C for 30 min. The B cell
receptor signaling pathway was stimulated by treating the cells
with the anti-IgM antibody at a concentration of 10 μg/mL and
incubated at 4 °C for 15 min. The cells were lysed, and the
protein components were extracted and equally divided into
three portions to carry out the rest of the procedure as a single
experiment.
Sample Fractionation and Phosphopeptide Enrich-
ment. Samples of “heavy” and “light” labeled whole cell
extracts (2.5 mg each) were normalized, mixed, and digested
with trypsin. The peptide sample was injected into an Agilent
1100 HPLC system and separated using either a 4.6 mm × 150
mm XBridge BEH C18, 3.5 μm particle reversed-phase liquid
chromatography (RPLC) column (Waters) or a 4.6 mm × 200
mm Polyhydroxyethyl A, 5 μm particle hydrophilic interaction
chromatography (HILIC) column (PolyLC Inc.). For the
HILIC fractionation, the 5 mg peptide sample was dissolved in
2 mL of solvent B (0.1% formic acid in acetonitrile), and the
sample was injected in 90% solvent B at a flow rate of 0.1 mL/
min. Solvent A consisted of 0.1% formic acid in water. After
loading the sample, the column was washed with 90% solvent B
for 15 min at 0.5 mL/min flow rate. Peptides were eluted in an
85% B to 65% B gradient for 40 min, followed by 65% B to
20% B gradient for 20 min at the same flow rate. For the RPLC
fractionation, the 5 mg peptide sample was dissolved in 4 mL of
solvent A (10 mM TMAB in water, pH 8), and the sample was
injected in 98% solvent A at a flow rate of 0.5 mL/min. After
loading the sample, the column was washed with 98% solvent A
for 10 min at a 1 mL/min flow rate. Peptides were eluted over
98% A to 60% A gradient for 60 min at 0.5 mL/min flow rate
(solvent B used for elution was 10 mM TMAB in acetonitrile,
pH 8). For each separation, 20 fractions were collected. For the
two sets of RPLC fractions, phosphopeptide enrichment was
carried out with PolyMAC-Zr and PolyMAC-Ti, whereas the
phosphopeptides in HILIC fractions were enriched only with
PolyMAC-Zr.
LTQ-Orbitrap Analysis. Peptide samples were redissolved
in 10 μL of 0.25% formic acid and injected into the Eksigent
nano LC Ultra 2D system. The reversed-phase C18 was
performed using an in-house C-18 capillary column packed
with 5 μm C18 Magic bead resin (Michrom; 75 μm i.d. and 12
cm of bed length). The mobile phase buffer consisted of 0.1%
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formic acid in ultrapure water with an elution buffer of 0.1%
formic acid in 100% CH3CN run over a shallow linear gradient
(from 2% CH3CN to 35% CH3CN) over 90 min with a flow
rate of 300 nL/min. The electrospray ionization emitter tip was
generated on the packed column with a laser puller (model P-
2000, Sutter Instrument Co.). The Eksigent Ultra 2D HPLC
system was coupled with a hybrid linear ion trap Orbitrap mass
spectrometer (LTQ-Orbitrap Velos; Thermo Fisher). The mass
spectrometer was operated in the data-dependent mode in
which a full scan MS (from m/z 300 to 1700 with a resolution
of 30 000 at m/z 400) was followed by 20 MS/MS scans (for
SILAC samples, 7 MS/MS scans were used) of the most
abundant ions. Ions with a charge state of +1 or undetermined
charge states were excluded. The mass exclusion time was 90 s.
Database Search. The LTQ-Orbitrap raw files were
searched directly against a human database using SEQUEST
or MASCOT on Proteome Discoverer (version 1.3, Thermo
Fisher). Proteome Discoverer created DTA files from raw data
files with minimum ion threshold 15 and absolute intensity
threshold 50. The peptide precursor mass tolerance was set to
10 ppm, and the MS/MS tolerance was set to 0.8 Da. Search
criteria included a static modification of cysteine residues of
+57.0214 Da and a variable modification of +15.9949 Da to
include potential oxidation of methionine and a modification of
+79.996 Da on serine, threonine, or tyrosine for the
identification of phosphorylation. Searches were performed
with full tryptic digestion and allowed a maximum of two
missed cleavages on the peptides analyzed from the sequence
database. False discovery rates (FDR) were set to 1% for each
analysis. The number of unique phosphopeptides and non-
phosphopeptides identified were then counted using an in-
house software. Phosphorylation site localization from CID
spectra was determined by PhosphoRS on Proteome
Discoverer 1.3. For SILAC experiments, in addition to the
above parameters, a dynamic modification of +6.020 Da was
added on arginine and lysine. The quantification method was
set to SILAC 2plex (Arg6, Lys6) and light/heavy ratios were
reported.
Data Analysis. Unique peptides were extracted on the basis
of the m/z value and the charge state using an in-house
software. The actual phosphorylation sites were determined by
the PhosphoRS score, and only the top scoring phosphor-
ylation site was reported for any phosphopeptide with
potentially ambiguous sites. Following the standard SILAC
quantification approach,10 the cutoff values for phosphorylation
changes were determined and above or below 2-times the
standard deviation from the mean was considered as a
significant change. To predict upstream kinases for identified
phosphosites, in-house software utilizing the kinase motifs
listed on human protein reference database was used.
Pathway Analysis. A list of proteins was extracted
corresponding to the peptides selected above. This list with
decreased and increased phosphorylation and the correspond-
ing SILAC ratios were submitted to Ingenuity Pathway Analysis
(IPA) (Ingenuity Systems). The IPA criteria were set to include
only known human cellular proteins and their direct
interactions. In addition, protein functions were predicted
using DAVID bioinformatics tool.
■ RESULTS AND DISCUSSION
PolyMAC-Zr for Phosphopeptide Enrichment. We
introduced recently PolyMAC-Ti for efficient capturing of
phosphopeptides.26 In addition to titanium, zirconium is
capable of effectively binding to phosphate groups, and this
property has been successfully explored for both phosphopep-
tide enrichment19,29 and DNA capturing30,31 using solid
supports. To further explore the utilization of zirconium ion
for phosphopeptide enrichment, we developed a soluble
nanopolymer-based reagent, PolyMAC-Zr (Figure 1a), poly-
amidoamine (PAMAM) generation 4 dendrimer functionalized
with Zr4+ ions. Hydroxylamine groups were attached to the
dendrimer, which were used as the “handle” to capture the
dendrimer onto aldehyde-functionalized agarose beads through
a rapid covalent reaction. During phosphopeptide enrichment,
a complex peptide mixture is incubated with the PolyMAC-Zr
reagent in solution, resulting in the rapid and selective binding
of phosphopeptides in the homogeneous solution. The
phophopeptide-bound PolyMAC-Zr reagent is then isolated
using the aldehyde-functionalized beads. Last, the bound
Figure 1. Basic structure and functional evaluation of PolyMAC-Zr.
The structure of PolyMAC reagent and the structural differences
between PolyMAC-Zr and PolyMAC-Ti. (a) Evaluation of PolyMAC-
Zr using DG75 cell lysates. (b) Comparison of three PolyMAC-Zr
phosphopeptide enrichment experiments showing the number of
phosphopeptides (blue) enriched in each experiment and the number
of nonphosphopeptides (red) identified in each experiment. (c)
Comparison of PolyMAC-Zr and PolyMAC-Ti for the number of
phosphopeptides enriched and the selectivity (average of 3 replicates,
phosphopeptides in blue, nonphosphopeptides in red). (d)
Phosphopeptide identification overlap of phosphopeptide enrichment
between any two PolyMAC-Zr experiments or PolyMAC-Zr and
PolyMAC-Ti experiments (3 replicates).
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phosphopeptides are eluted under basic conditions for mass
spectrometric analysis. The capability of the reagent to
effectively enrich phosphopeptides was first evaluated using a
simple mixture containing angiotensin II and phosphorylated
angiotensin II (Supporting Information (SI) Figure S1) and
then with a panel of peptides generated from phosphorylated
(α-casein, β-casein, and ovalbumin) and unphosphorylated
proteins (lactalbumin, β-lactoglobulin, catalase, hemoglobin,
and bovine serum albumin). Before enrichment, the majority of
peaks detected by MALDI-TOF analysis were nonphospho-
peptides. After the enrichment, only phosphopeptides were
observed (SI Figure S2).
To evaluate the performance of the new reagent for use in a
complex mixture, we further tested it with a whole-cell lysate
generated from the human Burkitt’s lymphoma B cell line,
DG75. A 100 μg sample of the cell lysate was digested with
trypsin and subjected to phosphopeptide enrichment by
PolyMAC-Zr. Among the various tested loading buffer
conditions, a solution consisting of 200 mM glycolic acid,
50% acetonitrile, and 1% trifluoroacetic acid was optimal for
high selectivity and recovery (data not shown). The PolyMAC-
Zr reagent captured over 1200 unique phosphopeptides from
100 μg of DG75 cell lysate with over 60% selectivity for
phosphorylated peptides (Figure 1b,c). The overlap of
identified phosphopeptides between any two experiments was
∼75%, demonstrating the excellent reproducibility of homoge-
neous capture with PolyMAC-Zr (Figure 1d), consistent with
previous studies with PolyMAC-Ti.26 On the other hand, the
overlap of phosphopeptides enriched by PolyMAC-Zr and
PolyMAC-Ti was <50% (Figure 1d), indicating each metal ion
enriched a unique set of phosphopeptides.
In-Depth Analyses of Syk-Dependent Phosphoryla-
tion in B Cells. PolyMAC-Zr was used in combination with
PolyMAC-Ti to investigate Syk-dependent phosphorylation in
B cells following anti-IgM stimulation of the BCR. Two
populations of DG75 cells were grown in SILAC media
containing either “light” or “heavy” (13C6-labeled) arginine and
lysine. One group of cells was treated with the Syk inhibitor,
piceatannol, and the other group was treated with DMSO as a
control. Both sets were stimulated with anti-IgM antibody to
activate the BCR signaling pathway. Equal amounts of protein
(2.5 mg) extracted from each cell population were mixed and
digested with trypsin.
To reduce the sample complexity, we used RPLC32 or
HILIC25 in the first dimension of peptide fractionation. HILIC
and RPLC are complementary separation methods,25,33 and we
used PolyMAC-Zr to enrich phosphopeptides after HILIC
fractions. The orthogonality of RPLC was achieved by
separating peptides at high (pH 8) and low pH (pH 2.6)
values in the two dimensions.32,34 Previously, this has been
successfully applied for both phosphopeptide and non-
phosphopeptide separations.32,34,35 Each RPLC fraction was
enriched for phosphopeptides using PolyMAC-Zr or Poly-
MAC-Ti before the LC−MS/MS analysis. Figure 2 summarizes
the total number of phosphopeptides, the number of unique
phosphopeptides obtained from each fractionation approach,
and the distribution of phosphopeptides in different fractions.
As expected, the unique phosphopeptides identified using
PolyMAC-Zr versus PolyMAC-Ti demonstrated only about
50% overlap. A total of 13 029 unique phosphopeptides
representing over 16 000 unique phosphorylation sites were
identified in this study. The distribution of serine, threonine,
and tyrosine phosphosites is illustrated in Figure 2c. The
relative abundances of 0.05%, 10%, and 90% have been
reported for phosphotyrosine, phosphothreonine, and phos-
phoserine, respectively. Here, we identified 437 (2.6%)
phosphotyrosine, 2447 (15.1%) phosphothreonine, and
13304 (82.2%) phosphoserine sites. The relative abundances
are close to expected values for phosphothreonine and
phosphoserine but significantly higher for phosphotyrosine.
Such differences have been reported in previous studies that
utilized extensive fractionation to enable identification of low-
abundance proteins that are usually phosphorylated on tyrosine
residues.10 We compared quantitatively the “light” to “heavy”
ratios of identified phosphopeptides between the piceatannol-
treated and untreated samples to assess the importance of Syk
to BCR-stimulated phosphorylation. Out of 13 029 unique
Figure 2. Summary of B cell phosphopeptide fractionation and
enrichment. (a) The number of phosphopeptides identified in each
fraction in three separation and enrichment combinations. RPLC and
HILIC fractions enriched by PolyMAC-Zr and RPLC fractions
enriched by PolyMAC-Ti. (b) Upper panel shows the phosphopeptide
overlap of RPLC fractions enriched with PolyMAC-Ti and PolyMAC-
Zr. Lower panel shows the overlap between RPLC and HILIC
fractions both enriched with PolyMAC-Zr. (c) The pie chart shows the
percentages of serine, threonine, and tyrosine phosphorylation sites
identified in the study.
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phosphopeptides, 1506 showed more than a 2-fold increase,
whereas 2340 showed more than a 2-fold decrease after
treatment with the inhibitor. These unique phosphopeptides
provided a list of 1982 phosphorylation sites with increased
phosphorylation from 1049 proteins and 2960 sites with
decreased phosphorylation levels from 1446 proteins (SI
Tables S1 and S2).
Regulation of Cellular Functions by Syk-Dependent
Phosphorylation. In the presence of an antigen, B cell
receptor (BCR) aggregates and transduces signals to the cell
interior by activating Src-family kinases Lyn, Blk, and Fyn, as
well as tyrosine kinases Syk and BTK. These participate in
signaling complexes that include adaptor proteins, such as
CD19 and BLNK, and signaling effectors, such as PLCγ, PI3K,
and VAV. Signals transduced through these components
activate multiple downstream signaling cascades, inducing
changes in cellular metabolism, gene expression, and
cytoskeletal organization. These signaling cascades can regulate
survival, tolerance, proliferation, or differentiation of B
cells.2,36,37 Therefore, it is important to understand the Syk-
dependent processes of these complicated signaling events.
Elucidation of these processes can be facilitated by examining
signaling events with and without the inhibition of Syk using
piceatannol. Proteins directly involved in these pathways
typically demonstrate decreased levels of phosphorylation
upon Syk inhibition. However, feedback loops and lack of
activation of phosphatases may result in increased levels of
phosphorylation in some proteins.36−38
To further understand the Syk-dependent changes in
phosphorylation, the nature of upstream kinases were predicted
on the basis of the sequences of phosphorylation sites using
software developed in-house, as shown in Figure 3a. A list of
kinase motifs was extracted from the human protein reference
database (HPRD),39 and upstream kinases were predicted for
all the phosphorylation sites identified with changing
phosphorylation levels. The normalized fraction of phosphor-
ylation sites for each kinase is illustrated in Figure 3a, where a
positive value indicates the fraction of phosphorylation sites
with increased phosphorylation and a negative value indicates
the fraction of phosphorylation sites with decreased phosphor-
ylation upon treatment with piceatannol. According to the
above analysis, calmodulin-dependent kinase motifs are found
only among the sites with decreased phosphorylation. Intra-
cellular calcium levels increase during BCR signaling1 and Syk
inhibition interrupts proper signal propagation,40 which may
lead to the decreased activity of calcium-dependent kinases.
AKT and NIMA kinase motifs are represented only among sites
with increased phosphorylation. AKT is activated downstream
of BCR engagement in B cells; therefore, a decrease in AKT
activity is expected upon Syk inhibition. However, this observed
increase in phosphorylation could be due to the fact that most
cultured lymphoid cell lines, including DG75, lack both PTEN
and SHIP1 and have constitutively active AKT.41−43
Furthermore, there are significantly higher numbers of CDC-
like kinase 1 (CLK1) and AMP-activated protein kinase
(AMPK) sites with decreased phosphorylation. AMPK is
Figure 3. Regulation of cellular functions by Syk dependent phosphorylation. (a) Distribution of consensus kinase motifs within the data set. (b) A
summary of B cell functions perturbed by Syk inhibition.
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known to be activated downstream of the T cell receptor
(TCR) in a manner dependent on CaMKKs and the Zap-70
substrates LAT and SLP76.44 CLK1 is a dual specificity kinase
expressed in the nucleus that is involved in mRNA splicing.45
Serine/arginine rich proteins are known substrates for this
kinase,46 and several such proteins show decreased phosphor-
ylation levels in our study. Interestingly, we identified RNA
post-transcriptional modifications pathway as one of the
perturbed networks upon Syk inhibition (Figure 3b, SI Figure
S3 and Table S3). Specifically, mRNA spicing factors,
ribonuclear proteins and splicing regulatory proteins show
significant changes in levels of phosphorylation.
Interestingly, Src-family kinases, polo-like kinase 1(PLK1),
and ataxia telangiectasia mutated kinase (ATM) substrate sites
are enriched among sites with increased phosphorylation. Syk
and Src family kinases are known to participate in signaling
cross-talk47 and may have nonredundant48 or opposing49 roles
in some pathways. Therefore, Syk inhibition may have affected
cross talk between Syk and Src kinases, resulting in increased
levels of Src family kinase-dependent phosphorylation. PLK1,
on the other hand, functions in centrosome maturation, spindle
assembly and cytokinesis. Prior experiments have revealed
autophosphorylation-dependent centrosomal localization of
Syk4,6,50 and colocalization of Syk and PLK1 at mitotic spindle
poles.51 Threonine phosphorylation on Syk by PLK1 has been
reported to be a part of an antiapoptotic mechanism, and the
disruption of the mechanism may have activated alternative
PLK1-dependent phosphorylation events.51 Furthermore, we
have identified centrosome organization as one of the functions
perturbed upon Syk inhibition (Figure 3b, SI Figure S4 and
Table S4)
A limitation in upstream kinase prediction is the lack of
known consensus sequences for the majority of kinases, and
therefore the study was restricted to a few kinases.
Furthermore, the substrate specificities of many kinases overlap,
making it difficult to attribute specific phosphorylation events
to a single kinase. Still, some of the kinase motifs show
significant enrichment among groups of sites with distinctive
higher or lower phosphorylation levels. On the other hand,
functional annotation provides complementary information
that can be correlated with phosphorylation changes of kinase
specific sites. For example, we have identified NPM1, NUDC,
and BUB1B which are PLK1 substrates during centrosome
organization. Therefore, it is likely that these kinases are acting
as nodes in various downstream pathways that are modulated
by Syk in B cells. Some of the important pathways and
functions are summarized in Figure 3b, and the protein lists are
given in the SI Tables S3−5. The function of Syk in the
immune system has been widely studied,52 and we observed the
B cell receptor (BCR) signaling pathway as the most perturbed
canonical pathway (SI Figure S5). Furthermore, other known
Syk-dependent networks, such as FcγRIIB, PI3K, PLC
signaling, NFAT regulation,2 and centrosome organization,
were also observed. More interestingly, we identified RNA post
transcriptional modification and the ubiquitin proteasome
pathway as novel potential Syk-dependent pathways.
Syk-Dependent Ubiquitination in B Cells. One of the
most intriguing networks in our data annotation is the ubiquitin
proteasome pathway (SI Figure S6 and Table S5). We
identified and quantified a significant number of phosphory-
lated nodes that function in this pathway, including E1, E2, E3
ligases, proteasome components, and deubiquitinases (DUBs).
The proteins belonging to the above categories are summarized
in Figure 4a with the SILAC fold change ratios obtained for
identified peptides. Among the different classes of proteins in
the ubiquitin proteasome pathway identified in this study,
DUBs are the most prominent group. The majority of DUBs
were found to contain significantly decreased levels of
Figure 4. (a) Phosphorylation on ubiquitin proteasome pathway proteins. The plot indicates the SILAC fold changes (x axis) of E1, E2, E3 ligases,
deubiquitinases, and proteasome components. Positive and negative values represent phosphorylation increase and decrease, respectively. Western
blots indicating Syk dependent ubiquitination. (b) Anti-ubiquitin Western Blot of proteins from DG75 B cells treated without (−) or with (+)
piceatannol. GAPDH was used as the loading control.
Analytical Chemistry Article
dx.doi.org/10.1021/ac500599r | Anal. Chem. 2014, 86, 6363−63716368
122
phosphorylation on one or more sites after Syk inhibition, such
as Y364 on ubiquitin specific peptidase 10 (USP10).
Deubiquitinases are tightly regulated both spatially and
temporally, similar to ubiquitin ligases, thus enabling careful
control over cellular signaling and protein stability.53
Phosphorylation is thought to be a key regulatory mechanism
for DUBs, as was demonstrated by a recent study of the human
deubiquitinase DUBA being controlled through phosphoryla-
tion at S177 by casein kinase (CK2),54 and USP25 has been
reported as a Syk substrate.55 This is the first report on the
regulation of ubiquitination by Syk.
Proteomics Analysis of Syk-Dependent Ubiquitina-
tion. To identify ubiquitinated proteins modulated by Syk,
DG75 cells were treated with MG132 to inhibit the
proteasome, and half of the cells were also treated with
piceatannol to inhibit the Syk activity. An examination of global
protein ubiquitination by Western blot analysis showed a
substantial decrease in protein ubiquitination following the
treatment of cells with piceatannol (Figure 4b). After cell lysis
and protein digestion, the ubiquitinated peptides were enriched
using an antibody raised against the diglycine motif, and the
resulting peptides were identified using LC−MS/MS. Quanti-
fication was achieved in a label-free manner using a synthetic
peptide library.56 This examination resulted in the identification
and quantification of over 1300 unique ubiquitination sites.
Although the overall level of ubiquitination was increased, after
setting the cutoff values at 2-fold changes based on the library
peptide normalization, we found that 360 and 520 peptides
showed decreased and increased ubiquitination representing
282 and 372 proteins, respectively (SI Table S6,7). It should be
noted that antiubiquitin antibody used for Western blots shows
stronger signals for polyubiquitinated proteins, whereas anti-
body against diglycine residue does not distinguish between
mono- and polyubiquitination. Hence, the ubiquitin proteomics
experiment may not perfectly match the Western blot results.
Our goal was to specifically identify proteins with decreased
ubiquitination upon Syk inhibition. A functional annotation was
carried out for the proteins with increased or decreased
ubiquitination. IPA analyses revealed that the proteins with
functions in RNA post transcriptional modifications, and
nucleic acid metabolism are prominent among proteins with
decreased ubiquitination, illustrated in Figures 5a and 5b,
respectively. For example, Pre-mRNA-processing-splicing factor
8 (PRPF8), heterogeneous nuclear ribonucleoprotein H3
(HNRNPH3), RNA-binding protein 39 (RBM39), and U2
small nuclear ribonucleoprotein B (SNRPB2) are among
proteins functioning in RNA posttranscriptional regulation
specifically by RNA processing and splicing with decreased
ubiquitination levels upon Syk inhibition.
■ CONCLUSION
Previous studies on Syk-dependent signaling events in B cells
focused mainly on tyrosine phosphorylation, thus limiting
information on potentially diverse Syk functions and down-
stream signaling events. Because Syk is an upstream kinase
within several signaling cascades, there are numerous
opportunities for serine/threonine phosphorylation events
that can be modulated by its kinase activity. Our integrated
approach of using complementary Ti- and Zr-based phospho-
peptide enrichment with RPLC and HILIC fractionation has
led to identification of over 16 000 unique phosphorylation
sites and quantification of nearly 4000 peptides with significant
phosphorylation changes. The annotation of corresponding
proteins reiterated known Syk-dependent functions and
suggested novel potential networks. Furthermore, canonical
pathway analysis suggested a significant influence of Syk activity
on ubiquitination network in B cells. The subsequent
examination of the dependence of ubiquitination on Syk
activity was carried out, and among more than 1300
ubiquitination sites identified, the data showed decreased
ubiquitination levels in RNA processing and splicing proteins
in response to Syk inhibition.
■ ASSOCIATED CONTENT
*S Supporting Information
Additional information as noted in text. This material is
available free of charge via the Internet http://pubs.acs.org.
Figure 5. Network analysis of proteins with decreased ubiquitination. (a) RNA posttranscriptional modification network. (b) Nucleotide metabolism
network: enzymes (blue), transcription regulators (green), peptidases (pink), transporters (purple), kinases (yellow), and other proteins (orange).
Protein names are given in the list of abbreviations in the Supporting Information.
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